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ABSTRACT 
 
 
Acute ischemic stroke (AIS) is a devastating disease leaving more than half of its victims 
disabled and causing nearly 5% of all deaths worldwide. In large ischemic strokes, a major 
cause of death is brain edema, which follows blood-brain barrier (BBB) leakage. The BBB 
ensures brain homeostasis in health and disease by limiting the entry of harmful blood-borne 
substances into the brain parenchyma. With a leaky BBB, the brain becomes devoid of 
protection from detrimental components of the circulating blood. 
 
The BBB leakage in animal models of ischemia–reperfusion has long been considered to be 
biphasic; however, a considerable amount of discrepancies exist among the studies. 
Knowing exact temporal changes of the BBB permeability (BBBP) is important for the 
management of stroke patients. When the BBB is open, BBBP alleviating therapies would be 
effective, neuroprotective or neurorestorative drugs would be introduced, and if the BBB is 
closed these drugs would not enter the brain. Practical and reliable biomarkers of BBBP 
status are needed. 
 
Stanniocalcins (STCs) are widely expressed in the brain and STC-1 expression is elevated 
in pathologies, such as hypoxia and focal ischemia. Recent data suggest a neuroprotective 
role for STC-1 especially trough hypoxic preconditioning (HPC). No previous data 
associate STC-1 and the BBB. 
 
We systematically evaluated disruption of the BBB following ischemia-reperfusion in a rat 
model of transient focal ischemia via suture occlusion of the middle cerebral artery for 90 
min. Firstly (I, II), animals were allocated to 15 groups after reperfusion (25 min to 5 weeks). 
Secondly (III), a group of animals were evaluated repeatedly from 2 h to 1 week after 
reperfusion. BBBP to both small (gadolinium) (I, II, III), and large (Evans blue) (I) 
molecules were quantified by magnetic resonance imaging and fluorescence, respectively. 
Lastly, the contribution of STC-1 to HPC and the BBB was explored using STC-1 deficient 
mice (STC-/-). 
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(I, II, III) After transient ischemia, the BBB leakage was continuous. Leakage to Evans Blue 
persisted up to 3 weeks and to gadolinium up to 5 weeks. Evans blue leakage slightly 
decreased at 36 and 72 h, gadolinium leakage was lesser at 25 min, 3 and 4 weeks. (IV) In 
STC-/- mice, HPC was effective in reducing lesion size, but these mice scored worse than 
wild type littermates. BBBP to Evans blue was not increased in STC-/- mice; neither under 
normal conditions, nor after hypoxia.  
 
To conclude, transient focal ischemia in rats triggers a continuous BBB leakage lasting for 
several weeks. Until the final closure of the BBB, no earlier transient closure occurs. This 
finding indicates a long therapeutic window opportunity in respect to BBB passage of drugs 
to treat stroke. BBBP imaging method used in these studies may be easily translated to 
clinics. STC-1 is not obligatory for hypoxic preconditioning and is not a determining 
component of the BBB. Yet, STC-1 is important for preservation of neurological function after 
transient ischemia.  
10 
 
 
 
 
1 REVIEW OF THE LITERATURE  
 
1.1 ISCHEMIC STROKE 
Stroke is a devastating disease. At the year 2010, stroke ranked the second leading cause of 
death, responsible for 8.9% of all deaths worldwide.1 It is estimated that each year nearly 6 
million people die from stroke and another 5 million are left dependant on others.2 Although 
the incidence of stroke is declining in many industrial countries due to improved preventive 
treatment, absolute number of strokes increases because of ageing. The world's 65-and-
older population is estimated to triple by midcentury, from 516 million in 2009 to 1.53 billion in 
2050.3 Europeans will likely continue to be the oldest people in the world: by 2050, 29 
percent of Europe’s population is estimated to be 65 years and older.3 Stroke burden 
calculated as disability-adjusted life years (a combination of years of life lost due to death 
and years of disability) is projected to rise by nearly two-fold from year 1990 to year 2020. In 
2001, disability-adjusted life years due to stroke were around 72 millions.4 In Finland stroke 
absorbs 7% of the health care budget.5 In the United States, the total cost of stroke in 2008 
was 34.3 billion and doubled in 2010, and the mean lifetime cost of ischemic stroke is 
estimated at $140,048 per patient.6 
 
Ischemic stroke accounts for 80 to 85% of all cases of stroke and results from a thrombotic 
or embolic occlusion of a cerebral artery. Over half of all ischemic strokes occur in the middle 
cerebral artery (MCA) territory.7 Etiologically atherosclerosis, embolism of cardiac origin, and 
small artery disease explain majority of cases.8 A minority is caused by dissections and over 
100 other causes. Eighty per cent of all ischemic strokes are preventable. Key risk factors for 
ischemic stroke are arterial hypertension, smoking, and hypercholesterolemia. Other risk 
factors can be classified as: traits (advanced age, male gender, African-American race, 
family history), medical conditions (diabetes mellitus, ischemic heart disease, atrial 
fibrillation, carotid artery disease, heart failure, peripheral arterial disease, thrombotic 
disorders, chronic kidney disease, sleep apnea), life style choices (obesity, excessive alcohol 
use, insufficient sleep, physical inactivity), and use of certain drugs (oral contraceptives, 
hormone replacement therapy, illicit drugs). 
 
11 
 
 
 
Intravenous thrombolysis with tissue plasminogen activator (t-PA) opened a new era in the 
management of acute ischemic stroke (AIS). Besides thrombolysis, the effect of stroke unit 
care, aspirin, and hemicraniectomy are evidence-based. Secondary prevention requires 
control of modifiable risk factors and etiology-oriented treatment (such as anticoagulation in 
atrial fibrillation, thrombophilia, and dissection, or carotid endarterectomy in significant large-
artery atherosclerosis).  
 
1.1.1 Pathophysiology of ischemic stroke  
The brain, although a tiny organ in size (2% of body weight), uses nearly one fifth of body’s 
oxygen and blood supply. Stores of energy lack in the brain making it highly dependent on 
continuous cerebral blood flow (CBF). Therefore, within minutes of cessation of blood supply 
to a territory of the brain, a complex sequence of pathophysiological spatial and temporal 
events (ischemic cascade) occurs.  
 
1.1.1.1 Core and penumbra 
Conventionally, core represents the irreversibly injured part of the ischemic lesion that 
destined to infarction and penumbra represents the region that is dysfunctional but 
salvageable if regional CBF is restored.9-12 Positron emission tomography techniques 
revealed: 1) the core with a CBF of <12mL/100g per min and 2) the penumbra with a CBF 
of 12 to 22mL/100g per min.13 A third benign oligemic area with CBF >22mL/100g per min 
also appeared13 (Figure 1). This oligemic tissue probably maintains its function for a very 
long time and is unlikely proceed to infarction.14 Animal studies using autoradiography to 
measure local CBF defined the core as a ischemic zone where CBF reduced to 0% to 20% 
of control, and the penumbra showed intermediate reductions of the flow, 20% to 40% of the 
control.15 In the core, protein synthesis seizes related to ATP loss and irreversible translation 
blockade. In the penumbra ATP is preserved, protein synthesis is decreased, heat shock 
proteins are produced, and probably an unfolded protein response occurs.16  
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Figure 1 Schematic presentation of ischemic core and penumbra. 
 
Pathologic outcome of focal ischemia is determined by two main factors: the degree of 
ischemia (rate of CBF decrease) and the duration of ischemia (time from CBF decrease to its 
recovery).17, 18 The probability of infarction is greater than 95% if early CBF falls below 25% 
of control.19 Early reperfusion preserves penumbra, but if the blood flow is not restored, the 
core extents to the entire penumbra. In most animal models, transient focal ischemia lasting 
4 hours or more induces similar infarct size to that induced by permanent ischemia, that is, 
penumbra does not exist after 4 hours. But in humans, some penumbra can still be detected 
up to 48 hours from the beginning of symptoms.20, 21 
 
Recent data suggest that not only penumbra, but also ischemic core is heterogeneous and 
dynamic. It is hypothesized that, in the early minutes and hours of ischemia onset, the core 
contains islets of injury (“mini-cores”), surrounded by salvageable viable tissue pockets 
(“mini-penumbras”).13 Microvascular heterogeneous responses to ischemia support this 
hypothesis.22 Saving the penumbra is the main target of acute stroke therapy, but this new 
theory implies that with extremely early interventions we may have impact on progression of 
infarct core as well.  
 
Evidence on cell death mechanisms in the core is scarce, because if not all, most of the 
agents failed to prevent damage in the core region. An exception is experimental use of 
antioxidant uric acid,23 which is as effective as thrombolysis,24 and suggests that a major 
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mechanism of cell death in the core is generation of free radicals. In general necrosis 
dominates in the core and apoptosis in the penumbra, but some ischemic cells may exhibit 
combined biochemical features of apoptotic and necrotic pathways.25 
 
1.1.1.2 Ischemic cascade 
Leading pathogenic mechanisms of ischemic cascade include energy failure, elevation of 
intracellular Ca2+ level, excitotoxicity, spreading depression, generation of free radicals, 
blood-brain barrier (BBB) disruption, inflammation, and apoptosis (Figure 2). These follow 
each other in a certain pattern, but not strictly in order, because they have overlapping 
features. Progression of ischemic brain injury may last hours to days, inflammation and 
apoptosis being the most long-lasting events.  
 
minutes
hours
days
weeks
ISCHEMIA
Energy failure
-acidosis
-Na+/K+ ATPase failure
-Extracellular K+
-Intracellular Ca2+
-Glutamate release
Excitotoxicity
-free radical formation
-BBB damage
-inflammation
-lipid peroxidation
Angiogenesis
Neurogenesis
Axonal remodeling
Necrosis
Apoptosis
 
 
Figure 2 Mainstream events following focal cerebral ischemia. 
 
First consequence of CBF reduction is the depletion of substrates, particularly oxygen and 
glucose, which causes accumulation of lactate via anaerobic glycolysis. Acidosis potentiates 
oxidative injury.26 With energy depletion membrane potential is lost and neurons and glia 
depolarize.27 Energy failure leads to perturbation of the Na+/K+-ATPase and Ca2+/H-ATPase 
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pumps; in addition Na+-Ca2+ transporter is reversed.28 Excitatory amino acids (mainly 
glutamate) are released into the extracellular space and intracellular levels of Na+, Ca2+, Cl- 
and extracellular level of K+ are increased. In contrast to core cells where anoxic 
depolarization occur, peri-infarct penumbral cells can repolarize due to partly preserved 
reperfusion, but depolarize again in response to increasing glutamate and K+ levels. 
Spreading depression defines depolarization starting within the ischemic core and 
extending outwards to surrounding tissue. It is an energy consuming process with the 
duration and number of peri-infarct depolarizations being correlated with the final infarct 
volume.29-31 
 
Excitotoxicity of accumulated glutamate and imbalance of ions lead to activation of a 
variety of Ca2+ dependent enzymes, including protein kinase C, phospholipase A2, 
phospholipase C, cyclooxygenase, calcium-dependent nitric oxide synthase, calpain, various 
proteases, and endonucleases. As a result, free-radical species and leukotrienes generate, 
leading to irreversible mitochondrial damage, inflammation, and both necrotic and apoptotic 
cell death. Due to the formation of mitochondrial permeability transition pore, the 
mitochondrial membrane becomes leaky. This follows two important events: first, a burst of 
free radicals32 and second, the release of cytochrome C.33 Free radicals react irreversibly 
with several cellular constituents such as proteins, double bonds of phospholipids, and 
nuclear DNA. Further, in conjunction with a weakened scavenger system, free radicals cause 
lipid peroxidation, membrane damage, dysregulation of cellular processes, and mutations of 
the genome. Cytochrome C is a central mediator of apoptosis (programmed cell death). 
Other triggers of apoptosis include oxygen free radicals, death receptor ligation, DNA 
damage, protease activation, and ionic imbalance. Pro-apoptotic signals lead to caspase 
activation. Activated caspases are protein-cleaving enzymes, which lead to characteristic 
DNA-laddering and cleavage of structural proteins (such as laminin, actin, gelsolin). 
Apoptotic cell, differing greatly from necrotic cell, is characterized by: shrinkage of the 
cytoplasm, marked condensation of chromatin, and fragmentation of the cell.34 Apoptotic 
cells are rapidly removed by phagocytosis without eliciting an inflammatory reaction.35 
 
An acute and prolonged inflammation reaction contributes to ischemic injury. Within minutes 
of arterial occlusion, residents cells (mainly microglia) are activated and along with other 
affected brain cells produce a plethora of proinflammatory mediators (tumor necrosis factor-
α,36 interleukin-6,37 monocyte chemoattractant protein-1,38 interleukin-1β,39 and granulocyte-
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colony stimulating factor40). Especially monocyte chemoattractant protein-1 appears as a key 
molecule in post-stroke inflammation that leads to transmigration of hematogenous 
leukocytes.38, 41 After the expression of adhesion molecules (including intercellular adhesion 
molecule 1 and selectins) at the vascular endothelium, neutrophils are the first inflammatory 
cells to arrive to the ischemic tissue, as early as within hours after reperfusion, followed by 
macrophages and monocytes within few days.42 Microvascular obstruction by neutrophils 
(no-reflow phenomenon) can worsen the degree of ischemia, production of toxic mediators 
by activated inflammatory cells and injured neurons can amplify tissue damage. Pathogenic 
role of neutrophils and other leukocytes in cerebral ischemia is still a subject of debate.42 
Inflammation seems to exert a dual role, acutely worsens the ischemic injury and in the long-
term proves beneficial through tissue remodelling.43 
 
Another important component of ischemic pathophysiology is edema formation. Edema is 
initially cellular (cytotoxic edema) and follows cellular metabolic disturbances. Cytotoxic 
edema is an important indicator of ultimate final infarct size.44 With the disruption of the 
BBB, intravascular fluid leaks into brain tissue (vasogenic edema), increases tissue volume, 
and proves number one reason of mortality in stroke. Mechanical or hypoxic damage of 
vascular endothelium, toxic damage of inflammatory molecules and free radicals, and 
especially destruction of the basal lamina by matrix metalloproteinases are potential causes 
of BBB disruption. This issue will be further discussed in a dedicated section. 
 
Late reperfusion can exacerbate the injury initially caused by ischemia. This so-called 
reperfusion injury was first noticed when three hours of focal ischemia followed by three 
hours of reperfusion in the rat have produced more damage than six hours of permanent 
ischemia.45 Reperfusion injury triggers alterations in production of various cytotoxic 
substances, including free radicals, excitatory amino acids, free fatty acids, proinflammatory 
cytokines, and adhesion molecules.46 Involved pathological processes include leukocyte 
infiltration, platelet and complement activation, postischemic hyperperfusion, and BBB 
disruption.47 In some AIS patients, thrombolysis follows fatal edema or intracranial 
hemorrhage; underlying event of these disastrous outcomes is reperfusion injury.  
 
A late phase in the pathophysiology of infarcted tissue is tissue remodeling. Days to weeks 
after a stroke, an active process of neural progenitor cell proliferation occurs. Neurogenesis 
has been documented in several focal ischemia models.48 Trophic factors, such as brain-
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derived neurotrophic factor and granulocyte-colony stimulating factor (G-CSF), promote 
neurogenesis.49, 50 Active angiogenesis is observed both in experimental animals and 
humans 3 days and further after an ischemic insult.51 Functional neuroimaging has 
demonstrated changes in a number of features of brain function related to recovery after 
stroke, including a period of functional growth characterized by demonstrable structural and 
functional changes in both the ipsilateral and contralateral hemispheres that last several 
weeks.52, 53 
 
1.1.2 Acute ischemic stroke therapy 
The main approach of treating AIS is timely recanalization. Thrombolytics or mechanical 
devices (not yet evidence-based) are used to open the occluded artery and thus to restore 
blood flow. In experimental scenario, a lot of of resources were spent on developing an 
effective neuroprotective agent, which would protect neurons from necrosis, by interacting 
with the components of ischemic cascade.  
1.1.2.1 Recanalization 
In 1996, intravenous recombinant t-PA became the first US Food and Drug Administration-
approved treatment for AIS. Original labeling requires the drug be given in 3 hours after 
symptom onset based on the National Institute of Neurological Disorders and Stroke t-PA 
trial.54 A restricted conditional license for the use of t-PA was granted in Europe in 2002 
allowing treatment within 3 hours in AIS patients younger than 80 years who also met other 
specified criteria. Results from the ECASS-III trial have since expanded time window to 4.5 
hours.55 Thrombolysis with t-PA significantly improves clinical outcomes at 90 days 
compared with placebo, for every 1000 patients treated, 97 more are alive and avoid 
disability.56 The sooner the t-PA is given, the greater the benefit is, especially within 90 min 
from symptom onset.57 A recent systematic review of 12 randomized trials of t-PA indicates 
the same fact, the greatest benefit is gained with early treatment, although some patients 
might benefit from t-PA up to 6 hours after stroke.56 Unfortunately, only a minority of AIS 
patients receive t-PA: in the U.S. 3% to 8.5%58 and in the capital area of Finland as much as 
15%59 of all AIS patients. The main reasons for this low rate of utilization of t-PA are 
economical and educational: Cost of acute stroke care is high (though probably cost-
effective60) and awareness level on stroke in general public is low. The risk of symptomatic 
hemorrhage (approximately 6%56) is another cause for withholding t-PA therapy.  
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Several novel thrombolytic agents are under progress. A recent successful example is 
tenecteplase, which was more effective than t-PA in a phase II trial.61 Desmatoplase in 
Acute Ischemic Stroke-3 (DIAS-3) and DIAS-4 phase III trials test the safety and efficacy of 
desmatoplase given three- to nine hours after symptom onset in patients with proved 
vascular occlusion.62 
 
Bridging therapy of concomitant use of both iv and intraarterial t-PA aims to combine the 
fast effect of iv use and higher recanalization rates of intraarterial use. Although yet an 
investigational technique,63 a recent meta-analysis found the bridging therapy safe and 
effective, suggesting that it may be the first choice of therapy in AIS patients with proven 
arterial occlusion.64 This hypothesis is tested in an ongoing phase III trial.65 
 
Endovascular revascularization is a local therapy of of therapy for AIS patients who have a 
contraindication for systemic thrombolysis or who do not respond to it. Large vessel 
occlusions are less prone to recanalization by t-PA.66 Clot retrieval with FDA-approved 
MERCI® Retriever has been an evolving treatment option due to positive results of MERCI 
trial.67 Pooled analysis of MERCI trial and the trial of combination of embolectomy and 
thrombolysis (Multi MERCI) provides additional evidence that increasing rates of 
recanalization improves clinical outcomes.68 Recently, mechanical embolectomy was not 
found superior to standard care within 8 h of symptom onset in large-vessel, anterior 
circulation strokes (MR-RESCUE).69 
 
The Penumbra system was approved for use in the United States in 2008 for “the 
revascularization of patients with acute ischemic stroke secondary to intracranial large vessel 
occlusive disease (in the internal carotid, middle cerebral artery M1 and M2 segments, 
basilar, and vertebral arteries) within 8 hours of symptom onset”. Penumbra system initiates 
recanalization by in situ suction of the clot. According to the pivotal study70 and publication of 
results from post-market experience71 the device seemed effective and safe. A phase IV 
study testing t-PA-Penumbra System combined therapy over standard t-PA therapy in 
anterior circulation strokes with a large clot is ongoing.72 
 
Ultrasound-enhanced thrombolysis increases recanalization compared with t-PA.73 A 
phase III trial in the USA (CLOTBUST-ER) is under progress.74 
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1.1.2.2 Neuroprotection 
To year 2003 over 1000 agents were tested in animals, out of which 60% exerted 
neuroprotection from focal ischemia.75 Nearly 200 clinical trials used candidate 
neuroprotective agents in humans with no success. Potential reasons of this translation 
failure have been extensively discussed elsewhere.76-81 Main reasons are the methodological 
differences between preclinical and clinical studies, inadequate quality of animal testing and 
the heterogeneity of stroke in humans compared to homogenous experimental strokes in 
animals.82-84 After these many failures to prove a neuroprotective efficacy of drugs tested in 
AIS patients, recently, the Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT) 
trial showed that neuroprotection worked in reducing ischemic infarcts after the endovascular 
repair of an intracranial aneurysm.85 This study perhaps will alleviate the ignorance of 
neuroprotection to treat AIS.  
 
Besides others,84 a group of candidates holds hope for neuroprotection: 1) Hypothermia 
combined with t-PA is tested for efficacy in a phase III trial86 and The European Hypothermia 
trial, EuroHyp-1, is also a randomized multicenter study to assess efficacy and safety of 
hypothermia in ischemic stroke patients,87) Free radical scavenging has become a 
promising approach with proven efficacy of NXY-059 in the first clinical trial SAINT-I.88 
Unfortunately SAINT-II was neutral,89 but indicated that treatment window should match the 
preclinical data and patient selection should be improved.90 Currently another free radical 
scavenger, ebselen, is tested in a phase III trial in patients with a cortical infarct.91 Drug will 
be started within 24 hours of stroke and given during14 days. Edaravone was introduced as 
the first free radical scavenger for the treatment of stroke92 and is widely used to treat acute 
ischemic stroke in Japan, although evidence from large-scaled clinical trials are lacking, and 
3) Minocycline, an antiinflammatory and antioxidant agent, was safe and effective in small 
open-label studies,93 a phase IV study has been terminated, but yet results are missing.94  
 
Animal data suggest that combining thrombolysis with neuroprotection may be superior 
to thrombolysis alone and may extend the time window of thrombolysis.95 Erythropoietin was 
harmful for this purpose,96 and currently uric acid97 and hypotermia98 are tested in phase III 
clinical trials. A novel approach of neuroprotection has proven effective in primates by 
selective inhibition of N-Methyl-D-aspartate receptor neurotoxicity.99 This high-quality 
preclinical work is giving hope that neuroprotection may be feasible in AIS patients and 
should be tested in a narrow population at first.100 
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For protecting neurons from dying, by only focusing on mechanisms of injury, we may have 
been seeing only half of the picture.101 Brain’s response to stroke is complex and includes 
multiple processes of endogenous repair and remodeling.51, 101, 102 It is suggested that 
candidate drugs for AIS should possess regenerative mechanisms of action in addition to 
neuroprotective actions, in order to achieve sustained neurological improvement.103 Thus, 
another group of drugs are designed to enrich neurorecovery and remodeling of the infarcted 
tissue. Among potential neurorestorative and neuroregenerative compounds, G-CSF has 
been extensively studied104 and appeared effective in reducing infarct size and enhancing 
functional recovery through its anti-apoptotic and neurogenesis inducing capacities.105, 104 
Despite these encouraging preclinical results, a phase II trial (AXIS-II) of G-CSF in AIS 
patient resumed negative.100 However, the drug awaits efficacy testing in chronic stroke 
patients.106 Cerebrolysin, a peptide preparation which acts as a neurotrophic factor, promotes 
neuroplasticity and neurogenesis in experimental models, but a phase III trial of cerebrolysin 
plus t-PA in AIS patients resumed negative.107 
 
1.1.3 Magnetic resonance imaging (MRI) in acute ischemic stroke 
Recent developments in AIS imaging have revolutionized our approach to acute stroke. 
Noncontrast computed tomography (CT), due to its wide accessibility, is most commonly 
used diagnostic tool for acute stroke diagnostics. Noncontrast CT has been sufficient as an 
imaging modality in thrombolysis candidates to receive tissue plasminogen activator in 3-
hour therapeutic window,54 but MRI may suit as a brain clock replacing the currently used 
epidemiological time clock when deciding patient recruitment to thrombolysis.108 Magnetic 
resonance is superior to CT to detect early ischemic changes109-112 and to detect involvement 
of more than one third of the middle cerebral artery territory.113, 114 Although CT remains the 
best method for detection of intracerebral hemorrhage, MRI with T2*can be equally 
sensitive.14  
 
MRI is noninvasive, patient compatible with only few contraindications, has relatively high 
spatial and temporal resolution with superior signal contrast, and clinical availability is 
constantly increasing. MRI may serve in AIS for several purposes: to ensure the diagnosis, to 
give insights on etiology, and to guide the selection of therapeutic approach.  
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1.1.3.1 Lesion evaluation by MRI  
Diffusion-weighted imaging (DWI) has revolutionized stroke research since this technique is 
extremely sensitive to the hyperacute phase of brain ischemia. Another advantage of DWI in 
stroke imaging is high sensitivity in detection of multiple acute ischemic lesions.115-117 
Perfusion-weighted imaging (PWI) is a semiquantitative method of evaluating brain 
perfusion, which provides imaging and measuring blood flow at the capillary level. 
Combination of DWI to PWI provides further insights on ischemic lesion evaluation. It is 
generally accepted that the difference between PWI-based hypoperfusion volume and the 
DWI-based lesion volume (the so-called mismatch) is operationally approximate the ischemic 
penumbra.118, 119  
 
It is thought that AIS patients with DWI-PWI mismatch may respond to thrombolysis beyond 
the therapeutic window. Unfortunately, first-ever randomized controlled study in this context 
(EPITHET)120 failed to prove effectiveness of t-PA in the 3- to 6 h treatment window 
concerning the primary end point (geometric mean relative infarct growth), probably due to 
spontaneously recovering subjects among mismatch patients.121 However, when a modified 
method for calculating mismatch volume (co-registration method) is used, reanalysis of 
EPITHET patients indicates attenuation in infarct growth.122 CT perfusion imaging-based 
detection of penumbra has driven the patient selection in the positive phase II trial of 
tenecteplase.61 A candidate group of patients to whom to apply mismatched-based 
thrombolysis are wake-up stroke patients (an estimated 25% of AISs occur during sleep123-
125).  
 
There is a lack of consensus regarding which PWI-derived parameter best defines 
hypoperfused region or predicts infarct growth.126-129 Other unsolved issues in MRI-based 
penumbra imaging are the optimal method of postprocessing,129 the use of an automated 
processing software,130 and method for delineation core and hypoperfusion. Optimization of 
PWI/DWI mismatch clearly requires further studies. 
 
A controversial issue is the clinical relevance of reversibility of DWI lesion.131 The definition of 
PWI/DWI mismatch is questioned after the recognition that the PWI boundary includes a 
region of benign oligemia and that a portion of the DWI core is potentially salvageable with 
rapid reperfusion.132 But, sustained DWI reversal seems infrequent and rarely clinically 
relevant by altering PWI/DWI mismatch.133 
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1.1.3.2 BBB disruption: contrast-enhanced imaging 
A wide spectrum of appearances of contrast enhancement of the ischemic lesion on the CT 
scans was noticed since late 70’s. Different patterns of enhancement (e.g. homogeneous or 
heterogeneous) were observed at different degrees (e.g. minimal to marked), and in different 
phases of the stroke,134-137 with a frequency varying from 26% to 95%.137 Enhancement was 
seen as early as first day and as late as 9 months after the onset of symptoms,136 but most 
often at two to three weeks after stroke.137 Even with modern imaging techniques the 
frequency of increased BBB permeability (BBBP) in AIS patients varies considerably (from 
20 to 88%).138-140 A higher frequency is recognized with dynamic imaging methods using 
quantitative approaches.  
 
An association of CT contrast enhancement to hemorrhagic transformation of the infarction 
was noted more than 30 years ago.141 In agreement with animal studies,142-145 early BBB 
disruption detected by parenchymal enhancement in human ischemic stroke was found 
highly specific for hemorrhagic transformation.146-148 With the increasing use of multimodal 
MRI and CT, parameters related to BBB damage are being discovered and recent studies 
often indicate an important role for BBBP imaging in prediction of hemorrhagic 
transformation. Dynamic perfusion CT is increasingly used for this purpose,140, 149-151 though 
there exists controversy about the optimal method of acquisition of the data (first-pass vs 
delayed-acquisition). If the permeability of the BBB is not large enough for blood cellular 
elements to pass, hemorrhage will not occur, but BBB leakage to much smaller molecules 
such as albumin, may cause edema.152 Perfusion CT data analyzed with a modified Patlak 
model was used to estimate BBBP for predicting malignant MCA and the need for 
hemicraniectomy.152 
 
Another imaging marker for BBB disruption was suggested as the so-called hyperintense 
acute reperfusion marker. This imaging finding was observed only on non-contrast follow-up 
examinations if gadolinium was administered during initial MRI and was defined as delayed 
gadolinium enhancement in the cerebrospinal fluid153, 154 on fluid-attenuated inversion 
recovery (FLAIR) images, indicating an early BBB disruption, increased risk of hemorrhagic 
transformation, and poor outcome.148, 155, 156 However, hyperintense acute reperfusion marker 
is a common finding in elderly stroke patients and is not necessarily associated with 
hemorrhagic transformation.157 
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DCE-MRI based quantification of BBBP via a kinetic model is not standardized yet. Kassner 
et al.139 applied Patlak model to DCE-MRI data for this purpose and evaluated BBBP in ten 
AIS patients (who did not undergo thrombolysis). Increased permeability was found in 
patients who developed hemorrhagic transformation.  
 
T2*-based BBBP MRI,158-160 despite its semiquantitative nature, is a strong alternative to 
DCE-MRI from a practical point-of-view, because perfusion MRI with T2*-WI is a part of 
routine imaging in most stroke units. Among several candidate T2*-based measures, relative 
recirculation, which identifies abnormalities in the contrast recirculation phase, provided 
comparable data to DCE-MRI and proved predictive in identifying patients with AIS who will 
proceed to hemorrhagic transformation.160 
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1.2 EXPERIMENTAL ISCHEMIC STROKE 
1.2.1 Why animal modeling 
Modeling of ischemic stroke serves for two main purposes: first, to disclose underlying 
pathological mechanisms of focal cerebral ischemia and then based on these deciphered 
mechanisms to develop novel therapies for stroke. Secondly, novel imaging techniques are 
explored and applied in animal models before their introduction into clinical practice. 
Thrombolysis161 and DWI162 are the mainstream examples of translational success from 
laboratory to clinics.  
 
Ischemic stroke is a very heterogeneous disease in human, varying in etiology, lesion 
location, and size and is complicated by concomitant diseases. Age, sex, and amount of 
collaterals are among several other variables affecting the outcome of ischemic stroke. 
Therefore, very large group of patients are required in clinical trials of stroke. On the other 
hand, in experimental stroke, a more homogenous disease is mimicked by strictly controlling 
variables, thus, with a small group of animals statistical power can be already reached, 
saving money and time. Rodents, less costly and more ethically acceptable than larger 
animals, are most often utilized in experimental stroke research, because of several reasons: 
the resemblance to humans in cerebrovascular anatomy, moderate size allowing easy 
manipulations, low costs, the relative homogeneity within strains, and last but not least, the 
accessibility for use by transgenic technology. In contrast to lissencephalic brains of rodents, 
large animals have gyrencephalic brains and considerable amount of neocortex akin to 
humans. Application of sophisticated methods such as evoked potential monitoring, 
electroencephalography, and functional imaging is easier in larger animals. It is 
recommended that positive rodent studies must be replicated in higher species before 
proceeding to clinical trials.163 Even among primates there are considerable differences in 
brain anatomy and vasculature, stroke in macaques may best represent human AIS.99 
 
1.2.2 Major rodent models of ischemic stroke  
There is a rich diversity of focal ischemia models, among which none is capable to mimic all 
aspects of human stroke, but most appropriate model can be chosen to address a specific 
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question. Model selection is especially important in preclinical drug developmental studies. 
Recommendations from the STAIR committee must be followed in designing such studies.163, 
164 Each model grants superiorities and shortcomings (for reviews see related articles165-169).  
 
Blocking of blood flow in the MCA is often aimed in animal models, because half of all 
strokes occur in the territory of this artery.7 Thromboembolic models mimic closely the 
disease from etiological aspect and they are suitable for testing thrombolytics. However, the 
most commonly used method of inducing focal cerebral ischemia is intraluminal occlusion of 
MCA by a surgical monofilament (suture model), which allows strict control on the timing of 
the reperfusion. Other models include surgical occlusion of the distal or proximal MCA, 
endothelin-1 induced ischemia, photothrombotic ischemia, and embolic models using 
artificial materials as embolus. Models requiring craniectomy are complicated by both 
negative side effects of exposing brain to the atmosphere and protective effect of 
craniectomy from malignant MCA infarction. 
 
Either permanent or transient ischemia is modeled. Permanent ischemic models represent 
clinical situation of nearly half of the AIS patients. Others experience transient ischemia by 
either spontaneous170 or therapeutic recanalization.171 In transient ischemia models, an 
ischemia period of 90 to120 min is most often used, because it induces sustained infarcts. 
Transient ischemia longer than 3 hours allows studying a specific aspect of the stroke, 
reperfusion injury, but do not contain penumbra.172 A candidate neuroprotective compound 
needs to be tested in both permanent and transient ischemia models, because of different 
underlying mechanisms in each type of ischemia.163 
 
1.2.2.1 Thromboembolic models 
Thromboembolic models use two main strategies to induce stroke: clot embolism from an 
extracranial artery and in situ clot formation in distal MCA. Originally autologous thrombi 
were injected into extracranial arteries to reach the more distal intracranial arteries.173, 174 In 
these earlier embolism models, infarcts induced by a shower of emboli were variable in size 
and early spontaneous recanalization occurred.174, 175 Important parameters for inducing 
consistent CBF decline and reproducible lesions are formation, composition, and final 
localization of the emboli. By mechanically processing a preformed thrombus, autolysis 
resistant fibrin-rich emboli may be achieved.176, 177 Others178 preferred injecting multiple fibrin-
rich autologous clots into the external carotid artery one after another leading to consistent 
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infarcts without spontaneous recanalization. Another method for increasing reproducibility of 
thromboembolic infarcts is endovascular delivery of an intact fibrin-rich embolus into the 
segment of the internal carotid artery near the origin of the MCA by intraarterial 
catheterization.179, 180 In situ thromboembolic stroke model ensures exact localization of the 
clot by microinjection of purified thrombin into the lumen of distal MCA.181 This model induces 
reproducible cortical infarcts in mice and responds to t-PA treatment when t-PA is introduced 
20 min after clot formation. In situ thrombus model avoids potential damaging effects of 
intraarterial catheterization, but necessitates a craniectomy. Yet efforts are spent to improve 
reproducibility in the thromboembolic model.182  
 
Thromboembolic models responding to thrombolysis183-185 suit for testing new thrombolytics 
and combination therapies of thrombolysis and neuroprotection for acute stroke.186 
Preclinical drug testing may use rabbit embolic models of stroke187 secondary to a rodent 
model. A large vessel thromboembolic occlusion model in rabbits may allow testing also 
mechanical devices in combination to thrombolysis.188 
 
1.2.2.2 Suture occlusion of the MCA 
Originally introduced by Koizumi et al.189 this model includes insertion of a monofilament 
suture into the internal carotid artery and advancing until it blocks blood flow to MCA. Suture 
MCAO model induces MCA territory infarctions involving both frontoparietal cortex and 
striatum with good reproducibility and reliability even among investigators of varying 
experience.190 Reperfusion is easily achieved by retracting the suture. The model is suitable 
to apply in the MRI scanner.191 Several modifications have been made to the initial model by 
using differently coated sutures or external carotid artery insertion of the suture.192, 193 Suture 
diameter, type of coating of the suture (with silicone or poly-L-lysine), and insertion length of 
the suture are among factors affecting the outcome. Size of the filament correlates well with 
the size of the infarct.194, 195 Silicone-coated suture causes larger and more consistent infarcts 
then uncoated suture induces.196, 197 The deeper the suture insertion is, the greater the 
achieved lesion is.198, 199 
 
Suture occlusion model carries some complications: Subarachnoid hemorrhage due to 
mechanical vessel rupture and hyperthermia due to hypothalamic injury may occur. Silicone 
coating of the suture and laser Doppler-flowmetry guidance may reduce the incidence of 
subarachnoid hemorrhage.200 Spontaneous hyperthermia can be avoided by limiting 
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ischemia duration to 90 minutes or less201 or adjusting suture tip to a size that does not 
occlude the hypothalamic artery.166  
 
Intraluminal suture MCAO model was suggested suitable for neuroprotective drug studies 
because a substantial penumbra exists within the first 60-90 min of injury.202 An MRI study 
showed, however, that the mismatch volume is larger and persists longer in thromboembolic 
model relative to permanent suture MCAO model in rats.203 Transient suture MCAO was also 
compared to embolic model combined with t-PA treatment (thrombolysis model).204 Even 
though infarct sizes were equal in these two models, perfusion recovers immediately and 
completely in the suture model, but slowly and incompletely in the thrombolysis model. The 
latter is associated with increased BBBP in the periphery of the infarct. Recently, serious 
concerns raised on the use of transient MCAO occlusion with suture model in preclinical 
studies.205 It has been argued that prompt recirculation achieved with this model is 
uncommon in naturally occurring strokes and the model misleads clinicians in translating an 
appropriately long time window for the agent under investigation. 
 
1.2.2.3 Other models 
Surgical methods aim to expose MCA by one of the several surgical approaches, among 
which orbital route is less traumatic.206 While electrocauterization of a portion of MCA results 
in permanent occlusion, the use of microclips and ligature snares allows reperfusion.207, 208 
Originally induced by frontoparietal approach,209 distal MCAO at the rhinal fissure spares 
lenticulostriate branches and leads only a restricted cortical infarction in rats. Tamura’s 
subtemporal approach210 gained a greater acceptance because with Tamura’s method more 
proximal regions of the MCA are accessible and infarcts are more reproducible. Not only the 
site, but also the length of the ligated portion of MCAO affects the outcome.211 To overcome 
variability in infarcts several modifications to surgical MCO have been proposed: tandem 
occlusion of the distal MCA and ipsilateral common carotid artery,212 tandem occlusion of the 
distal MCA and bilateral common carotid arteries (three vessel occlusion technique),207 and 
distal MCAO with temporary clip compression of both common carotid arteries.213, 214 Orset et 
al.181 have utilized temporal approach in their in situ MCA thrombosis model. Main handicap 
of surgical methods is their invasiveness. Additionally, they require good surgical skills and in 
transient surgical models recanalization is abrupt as in the intraluminal suture method. On 
the other hand, the site of occlusion is well-controlled.  
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In models of non-clot embolus, many compounds or materials were used as artificial 
emboli.215-219 Embolization with multiple microspheres187, 220-222 has been proposed to 
simulate atheromata and fat embolization. It induces permanent ischemia, infarct maturation 
is slower (i.e. penumbra persists longer223) than MCAO models, and infarcts are multifocal 
and heterogeneous.224 
 
In photothrombosis models, after systemic intravenous injection of a photoactive dye 
(traditionally Rose Bengal), a cortical brain area is irradiated by a light beam at a specific 
wavelength through the intact skull.225 Resulting perioxidative damage to the endothelium 
causes platelet adhesion and aggregation in both pial and intraparenchymal vessels within 
the irradiated area.226 Originally, this model induces cortical ischemic lesion with acute 
severe endothelial cell damage, BBB disruption, and edema formation.227 Additionally, 
ischemic lesion involves relatively restricted penumbral area, because of the associated end 
arterial occlusion. However, a variation of the original phothrombotic model, ring model,228 
successfully induces a penumbra-like lesion.229 Use of thinner ring irradiation may allow 
achieving late spontaneous reperfusion and a morphological tissue recovery.230 Another 
modification was made to occlude the MCA,231 simply MCA was exposed surgically and 
irradiated after the injection of the photoactive dye. In this variant, although penumbral part of 
the lesion is also minimal,232 a therapeutic effect of rtPA has been shown.233 Advantages of 
the cortical phothrombotic models are control on the location and size of the lesion, and low 
mortality. 
 
Endothelin-1 (ET-1) is a potent vasoactive peptide, which produces a marked 
vasoconstriction.234 Either by subtemporal approach235 or intracerebral injection technique,236 
ET-1 application onto MCA provides significant decrease of CBF in the MCA territory, 
resulting in an ischemic lesion pattern similar to that induced by direct surgical MCAO.236, 237 
Direct cortical application of ET-1 induces a semicircular infarct involving all layers of the 
neocortex.238 Endothelin-1 induced MCAO model mimics slow recanalization (lasting 
approximately 4 hours) in a dose dependent manner of applied ET-1.237, 239 Therefore, less 
control on the ischemia duration and intensity are disadvantages of the model. Furthermore, 
it is not suitable for testing thrombolysis. 
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A number of animal models exist to study posterior circulation strokes;240 more or less 
invasive embolic models were described.241, 242 A main handicap of modeling ischemic stroke 
originating from posterior circulation is lesser reproducibility compared to MCAO models.163 
 
1.2.3 Preconditioning 
1.2.3.1 Ischemic tolerance 
Introducing the brain a nonlethal insult allows it to be prepared for the next ischemic insult, 
i.e. preconditions the brain. Preconditioning triggers a defense mechanism as a product of 
genomic reprogramming, which renders brain tolerant to the final lethal injury. This new 
defense program may attenuate almost all steps of ischemic cascade; additionally, innate 
survival mechanisms and endogenous repair mechanisms are enhanced.243 
 
Ischemic tolerance occurs in two temporally distinct windows: early tolerance can be 
achieved within minutes, but wanes also rapidly, within hours; delayed tolerance develops in 
hours and lasts for days. The main mechanism involved in early tolerance is adaptation of 
membrane receptors, whereas gene activation with subsequent de novo protein synthesis 
and genetic reprogramming dominates delayed tolerance.244 Data on early ischemic 
tolerance in the brain are scarce,245-249 ischemic tolerance occurs in the brain predominantly 
with the delayed pattern. Cross tolerance, in which one type of insult promotes protection 
from a subsequent different type of insult, has been documented in the brain in many 
variations.250 Hypoxic preconditioning is a well-known example of cross tolerance. 
 
1.2.3.2 Hypoxic preconditioning 
A brief exposure to systemic hypoxia (i.e. hypoxic preconditioning; HPC) prior to transient 
MCAO reduces infarct volume, blood-brain barrier disruption, and leukocyte migration.251, 252 
Hypoxic treatment was first time used as a preconditioning trigger in a hypoxia-ischemia 
model in neonatal rats.253 Later, HPC was proven protective from both transient and 
permanent focal cerebral ischemia.254, 255 Sublethal hypoxia (11% oxygen for two hours) 
applied 48 h prior to transient focal cerebral ischemia protected nearly half of the tissue-at-
risk from undergoing infarction in several strains of mice.254 Compared to permanent 
ischemia alone, hypoxia applied 24 h prior to ischemia results in 30% smaller infarcts.255 
Single applications of varying hypoxia durations (1, 3, or 6 hours) are similarly efficient, but 
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protective effect abolishes after 72 hours.255 Repetitive hypoxic treatment, however, may be 
protective from focal ischemia up to 4 to 8 weeks.256, 257 
 
The mechanisms of hypoxic preconditioning and ischemic tolerance are still being 
elucidated. Hypoxia-induced tolerance in brain is not blocked by glutamate receptor 
antagonists, but is blocked by inhibitors of RNA and protein synthesis.258 A key factor in HPC 
is the hypoxia-inducible factor-1 (HIF-1). As early as 1 hour after hypoxia and maximally at 6 
hours, expressions of many HIF-1-regulated genes are increased.259 Hypoxia stabilizes alpha 
subunit of HIF-1, which enters the nucleus in a dimerized form and results in the induction of 
HIF target genes. Several HIF target genes contribute to protection from ischemia,255, 258, 259 
and their products are involved in a wide range of adaptive and pro-survival events, including 
cellular metabolism, proliferation, vascularization, iron homeostasis, and glucose 
metabolism.243, 260 However, in neuron-specific HIF-1alpha-deficient mice, protective effect of 
hypoxia from subsequent focal ischemia was significantly attenuated, but not completely 
abolished, suggesting that alternative mechanisms of neuroprotection are also implicated in 
HPC.261 Recently microvascular sphingosine kinase activity was found as an important 
trigger of hypoxic preconditioning.262 Blocking sphingosine kinase activity nullifies protective 
effects of prior hypoxia from transient ischemia. Chemokine signaling seems to be another 
critical mediator to the induction of hypoxic preconditioning-induced ischemic tolerance. Mice 
that lacked monocyte chemoattractant protein-1 also lost the capacity to become ischemia 
tolerant, although they received hypoxic treatment.251 
 
1.2.4 Outcome measures 
In contrast to human studies, where primary outcome is usually neurological improvement at 
3 months, experimental stroke mostly focused on the acute phase of ischemia and the main 
determinant of the outcome has been infarct volume within few days after the onset of 
ischemia, mostly ignoring functional outcome.263 If the model includes mild ischemia, lesion 
progression is slow, 264 or if a neuroprotective drug265 or a preconditioning regimen is tested, 
therapeutic effect may be transient;266 therefore, long-term outcomes should also be 
evaluated in such circumstances. Data from preclinical studies suggest a poor correlation 
between pathologic and functional improvements.267 Despite the lack of infarct size 
improvement, behavioral assessment might reveal effectiveness of a neuroprotective 
drug.268, 269 Lack of correlation between different outcome measures indicates that 
behavioral, neurological, and histological endpoints are conjointly necessary. 
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1.2.4.1 Infarct volume 
Infarct volume is traditionally evaluated post mortem with hematoxylin-eosin staining (i.e. the 
gold standard histological method) or with less costly 2,3,5-triphenyltetrazolium chloride 
(TTC). Other staining methods (Cresyl violet270 or silver staining271) are also available to 
delineate the extent of the ischemic lesion. Image analyzing systems allow manual, 
semiautomated, or fully automated delineation of the lesion area,272 273 after which lesion 
volume is calculated by multiplying with slice thickness. The larger the infarct, the more 
pronounced the edema and enlargement of the injured tissue by edema results in 
overestimation of the infarct volume. Thus, ischemic volume should be calculated with the 
correction of edema,274 especially in models using proximal occlusion of the MCA for periods 
longer than 60 min. Besides absolute infarct volumes, the percentage of the hemisphere 
undergone infarction can be reported to facilitate comparison of the data from different 
laboratories.  
 
In vivo MRI enables monitoring lesion progression by repeated imaging. With DWI sequence 
ischemic lesion can be identified as early as 3 min after the onset of ischemia191 and MRI-
based lesion volume at 72 h correlates well with the TTC-based infarct volume.275  
 
1.2.4.2 Neurological status 
Motor deficits are relatively objective end points of a rat stroke model and can be evaluated 
by a number of easy and quick methods.192, 211, 276 Tests to examine the effects of focal 
ischemia on more refined sensorimotor functions include: limb placing, beam walking, grid 
walking, rotarod, sticky label test, and staircase test.277 A number of cognitive tests are also 
available, among which Morris water maze is the prototype.278 However, in the MCAO model, 
spatial memory deficits seem minimal and watermaze impairments may be attributable to 
sensory and motor deficits.279 
 
Recently a tendency rose to use composite scores for functional evaluation in rodents. Such 
an increasingly used evaluation is the modified neurological severity scores, which includes a 
composite of motor (muscle status and abnormal movement), sensory (visual, tactile, and 
proprioceptive), reflex, and balance tests.280 Despite the simplicity of administering the tasks, 
deficits may be specific to a certain modality or function, and could be masked by the 
composite score.281 In addition, the reflexes tested in the modified neurological severity 
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scores (pinna and startle reflexes) are irrelevant to the damage induced with MCAO. 
 
Following points should be considered to ensure a successful functional evaluation after 
stroke in a rodent model: 1) The chosen battery of functional assessments should be able to 
detect even mild impairments, 2) it is important to obtain baseline data before experimental 
manipulations, 3) for tasks that require pre-training, animals must be properly trained before 
surgery, 4) experimentalist should be blind to treatment conditions to help eliminate bias.281 
 
1.2.5 Sources of variability in experimental ischemic stroke  
Age and sex of the animals should be considered. Rodent stroke studies mostly subjected 
young males.263 Female rats compared to male rats sustain smaller infarcts after MCAO, 
even in the presence of an additional pathology, such as diabetes and hypertension.282-285 
This is due to the protective effect of estrogens,286 which is lost after ovariectomy.285 Stroke 
pathophysiology differs between the aged and young rats. Ischemic stroke in aged rats are 
associated with increased ischemia/reperfusion injury, earlier disruptions of the blood-brain 
barrier, exacerbated neuronal degeneration, higher mortality, reduced functional outcome, 
and reduced angiogenesis.287-290 Response to t-PA291 or to a neuroprotective agent may also 
vary depending on the age of the animal.292, 293 Effectiveness of a neuroprotective agent in 
aged animals50 illustrates a larger target population for such candidate drug.  
 
Strain-dependent alterations in ischemia susceptibility are well-recognized.294-298 Fischer rats 
are quite unsuitable for suture MCAO.295 Sprague-Dawley rats are most often used in stroke 
research, but with very variable results.166 Strain of the rat may be a factor affecting the 
outcome in preclinical drug studies.299-301 Some authors suggest Wistar Kyoto rat the best 
choice, because it has a sustained vascular anatomy and its genetic relationship to the 
spontaneously hypertensive stroke-prone strains makes Wistar Kyoto rat an ideal stepping 
stone for later preclinical evaluations.166 
 
The spontaneously hypertensive stroke-prone rats are species susceptible to develop 
larger and much less variable infarcts following MCAO compared to other rat species.296, 302 
In these rats, cortical infarcts and cerebral hemorrhages occur spontaneously, but 
predominant lesions are small subcortical lesions, most probably with an initiating event of 
BBB disruption rather than vasospasm, thrombosis, or ischemia.303 Therefore, spontaneously 
hypertensive stroke-prone rats are good candidates for lacunar stroke modeling,304, 305 but 
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high mortality rate restricts their use in MCAO models. 
 
Once a candidate stroke drug is proven efficient in otherwise healthy animals, next step is to 
know whether it retains efficacy in the face of comorbidities, such as diabetes and 
hypertension. Animal experiments of neuroprotection rarely involve testing in these 
conditions,75 although, rodent models of both type 1 and type 2 diabetes306 and 
hypertension307 are available. Type I diabetic rats subjected to thromboembolic ischemia 
exhibited resistance to thrombolytic reperfusion, larger infarction volumes, increased 
intracerebral hemorrhage,308 and higher BBB leakage.309 Type 2 diabetic rats showed a 
defective angiogenesis after transient ischemia.310 Using these models one can decipher 
how these comorbidities can influence the pathophysiology of stroke. 
 
Several physiological parameters need to be monitored and regulated if they alternate 
during an experiment of stroke. High blood glucose levels are not allowed because a body 
of evidence suggest a role for hyperglycemia concerning deterioration in infarct size, 
functional outcome, and blood-brain barrier damage.311-315 Body temperature is easily 
monitored with a rectal probe. Animals should be kept normothermic for the reasons that 
hyperthermia worsens the ischemic damage316 and hypothermia is neuroprotective.317 
However, a set of animals should be used for testing whether the experimental treatment 
itself is inducing hypo- or hyperthermia. Arterial blood pressure and gases should be 
closely followed, particularly in deeply anesthetized animals.  
 
Many of the commonly used anesthetics provide some degree of neuroprotection318 and 
most of the volatile anesthetics trigger ischemic tolerance,319 for reasons why experimental 
groups off animals should receive the same anesthetic and the possibility that anesthetic 
may interfere with the effects of a candidate neuroprotectant should be considered. 
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1.3 BLOOD-BRAIN BARRIER 
1.3.1 Structure and functions, neurovascular unit 
The concept of the BBB date back to the late 18th century when Paul Ehrlich noted that an 
intravenously injected dye leaked into all the organs except into the central nervous 
system.320 The nature of the BBB was debated well into the 1960s.321 Current understanding 
of the basic structure of the BBB is built on an electron microscopic discovery, that capillary 
lumen bridged by tight junctions (TJ) form a continuous, impermeable membrane, which 
forms the primary anatomical substrate of the BBB.322 The concept of the BBB has continued 
to be refined over the past few decades. Currently, it is growingly recognized that, not only 
cerebral microvascular endothelial cells, but multiple cells (such as glial cells, pericytes, and 
neurons) constitute together with extracellular matrix a functional unit, “neurovascular unit”, 
of which the integrity is essential to maintain homeostasis (Figure 3).323, 324 Concerted 
synergism of the elements of the neurovascular unit gives rise to a BBB, which is simply 
more than the sum of its parts. The human adult BBB has the same approximate surface 
area as a tennis court, and a fifth of the cardiac output, that is, 1 to 1.5 L blood, passes over 
it every minute at rest.325 Microvessels involve an estimated 95% of the total surface area of 
the BBB. This barrier makes the brain practically inaccessible for lipid-insoluble compounds, 
such as polar molecules and small ions, for which transport have to take place via carrier-
mediated or vesicular mechanisms. Gases and small lipophilic molecules can diffuse through 
the BBB.  
 
 
Figure 3 Schematic diagram of 
neurovascular unit that comprises 
neurons, endothelial cells, astrocytes, 
and pericytes. Basal membrane 
surrounds endothelial cells and 
pericytes. 
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1.3.1.1 Endothelial cells and pericytes 
Endothelial cells of the BBB are distinguished from other endothelial cells by a number of 
aspects: the presence of TJs,322 high number of mitochondria,326, 327 small number of 
caveolae (membrane-bound vesicles),328 lack of fenestrations,329 minimal pinocytotic activity, 
and near absence of vesicular transport.330 The transendothelial electrical resistance, which 
restricts ion permeability, is in the range of 1000–5000 Ω cm2 in brain capillaries,331 more 
than a hundred times higher than in noncerebral capillaries. Maturation of the BBB 
necessitates endothelial cell expression of specific molecules (overviews exist332, 333). 
Specific transport systems selectively expressed in the membranes of brain capillary 
endothelial cells mediate the directed transport of essential nutrients into the central nervous 
system or of toxic metabolites out of the central nervous system.332 Transendothelial 
transport occurs, among many others, for hexoses (glucose, galactose), amino acids, 
purines, and nucleosides. A receptor-mediated transport system resides in brain endothelial 
cells for many substrates, including low-density lipoprotein, insulin, immunoglobulin G, and 
transferrin. Active efflux pumps are also expressed in endothelial cells. Three classes of 
transporters are implicated in the efflux of drugs from the brain:1) monocarboxylic acid 
transporters, 2) organic ion transporters, and 3) multidrug resistance transporters (prototype 
is P-glycoprotein).334 Enzymatic roles of the endothelial cells comprise another level of barrier 
between cerebral circulation and brain (“metabolic BBB”). A well-known example of this 
enzymatic barrier is DOPA-decarboxylase within the endothelial cells, which restricts the 
transfer of dopamine from blood to brain.  
 
Pericytes are located at the abluminal surface of the microvessels and encircle with their 
processes 30 to 70% of the capillary wall.335 They are ensheathed by basal lamina, which 
separates them from endothelium and astrocyte end-feet (Figure 3). There is approximately 
one pericyte for every two to four endothelial cells. Pericytes are multifunctional in the brain 
and they are required for both the stabilization and maturation of the capillary, as well as the 
BBB.336 Pericytes-lacking mice develop perinatally brain edema and hemorrhages due to 
increased BBBP,337, 338 of which one essential reason is deficient TJ formation. In mouse 
brain during ischemia, pericytes contract and impair capillary flow.339 Additional roles are 
suggested for pericytes in angiogenesis and neurogenesis occurring after stroke.336 
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1.3.1.2 Basal lamina 
The basal lamina separates endothelial cells of brain vasculature from its neighboring cells 
(Figure 3). It is composed of different extracellular matrix proteins, including collagen and 
laminin. Matrix adhesion receptors, which are essential for the maintenance of the integrity of 
the BBB, are expressed in the endothelial cells, neurons, and glia. Integrin and dystroglycan 
receptors appear to bind endothelial cells and astrocyte end-feet to the individual intervening 
matrix components.340  
 
Focal ischemia initiates a rapid loss of integrity of the extracellular matrix within the 
microvasculature and matrix adhesion receptors.340 With the disappearance of antigens of 
the three main constituents of the basal lamina (laminin, fibronection, and collagen type IV), 
the basal lamina loses its integrity.22, 341 Loss of the matrix proteins has been associated with 
the rapid generation of members of four protease families: matrix metalloproteinases 
(MMPs), serine proteases, cysteine proteinases, and heparinase, sources of which have not 
entirely been worked out.342 Several lines of evidence from animal stroke experiments 
suggest involvement of MMP-2 and MMP-9 in digestion of basal lamina leading to BBB 
disruption, edema, and hemorrhagic transformation.341, 343-348 Additionally MMPs contribute to 
the disruption of TJ proteins.349, 350 Caveolin-1 was recently discovered as an upstream 
regulator of MMP activity after ischemia-reperfusion injury.351 A systematic review of AIS 
patients indicated that serum MMP-9 levels are significantly correlated with infarct volume, 
severity of stroke, and functional outcome, and MMP-9 may be a predictor of development of 
intracerebral hemorrhage in patients treated with thrombolytic therapy.352 
 
1.3.1.3 Tight junctions 
TJs appear in endothelial and epithelial cells as a system of fusion with two main 
parameters: the complexity of strands and the association of the particles with the inner (P-
face) or outer (E-face) lipidic leaflet of the membrane. Brain endothelial tight junctions are the 
most complex in the whole body vasculature, with respect to high number of strands (which 
reflects high transcellular electrical resistance) and high P-face association. TJs, along with 
adherens junctions, form a circumferential zipper-like structure between endothelial cells, 
limiting paracellular passage of hydrophilic molecules. The degree of tightness of this zipper 
varies within the microvasculature, as capillary endothelium proceeds to post-capillary 
venous endothelium, strand complexity of TJs is reduced. The detailed molecular structure of 
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the TJs and the impact of ischemia on BBB with respect to TJs are reviewed elsewhere.353-357 
Here, only main components of TJs are briefly summarized. 
 
Junctional proteins can be categorized as transmembrane proteins and peripheral 
membrane proteins. Transmembrane components of the TJ include junctional adhesion 
molecule (JAM)-1, occludin, and claudins. Peripheral membrane proteins associate with TJs 
in the cytoplasm; these are membrane-associated guanylate kinase –like proteins, including 
zonula occludens (ZO)-1, ZO-2, and ZO-3.  
 
Occludin, the first transmembrane TJ protein discovered,358 has four transmembrane 
domains with two extracellular loops. Occludin is not mandatory for TJs or TJ strands to 
form,359 however, presence of occludin is correlated with increased transcellular electrical 
resistance and decreased paracellular activity.360 It is a critical regulatory protein for 
mediating TJ responses in disease states.357 The carboxy-terminal of the occludin binds to 
ZO, which in turn binds to the actin cytoskeleton, localizing it to the cellular membrane. 
Dissociation of occludin from ZO may be related to increased BBBP after ischemia.361  
 
The claudins, which share a similar membrane topography with occludin, but no sequence 
homology, are believed to be the major transmembrane proteins of TJs, because occludin 
knockout mice are still capable of forming these inter-endothelial connections, while claudin 
knockout mice are nonviable362 and claudin-5 gene lacking mice show a loss of BBB 
integrity.363 It is believed that claudins are responsible for the regulation of paracellular 
permeability through the formation of paired strands.355 Among more than 20 identified 
members of claudins, at least four (claudin-1, -3, -5, and -12) are expressed by BBB 
endothelial cells, however, claudin-1 seems to be not targeted to the TJ.355 Claudins interact 
directly with all ZO proteins. Claudin-5 and occluding mRNA expression are decreased and 
these TJ proteins are degraded by MMP-2 and MMP-9 early after focal ischemia.349 
 
JAMs are a family of immunoglobulin superfamily proteins that localize within the intercellular 
cleft of TJs. JAMs participate in the assembly and maintenance of the TJs,357 overexpression 
of JAMs in cells that do not normally form TJs increases their resistance to the diffusion of 
soluble tracers, suggesting a role for permeability control for JAMs.364Among several JAMs 
identified, JAM-A is highly expressed in the cerebrovasculature, but the status of JAMs after 
stroke has not yet been studied. 
37 
 
 
 
 
ZO-1 was the first peripheral membrane component identified at TJs.365 Since then, many 
further cytoplasmic components of TJs have been described, such as ZO-2, ZO-3, cingulin, 
and afadin among others. Because the vast majority of experiments, addressing the role of 
these proteins for TJ formation and regulation, were performed with epithelial cells, the BBB 
related information on peripheral membrane proteins of TJs is still limited. ZO-1 acts as a 
central organizer of the TJs, linking its carboxy-terminal region to the actin cytoskeleton. 
Further, ZO-1 translocation from TJ membrane to cytoplasm is associated with an increased 
barrier permeability.366 ZO-1 expression is reduced 24 h after focal cerebral ischemia and 
this correlates with increased MMP-9 activity.346, 351, 367 MMP inhibition, nitric oxide synthase 
inhibition, and knocking-out of MMP-9 gene, all prevent focal ischemia-induced ZO-1 
degradation and BBB disruption. 
  
1.3.1.4 Adherens junctions 
Adherens junctions are primarily composed of vascular endothelial cadherin, which is 
linked to cytoskeleton via catenins. The role of catenins in adherens junctions bears 
resemblance to that of ZOI proteins in TJs.362 Disruption of adherens junctions at the BBB 
can result in increased BBBP.321 Adherens junctions are functionally and structurally linked to 
TJs, presumably playing an important role in the localization and the stabilization of the TJs 
by forming a continuous belt localized near the apical end of the junctional cleft, just below 
the TJs.368 The contribution of vascular endothelial cadherin and the catenins in BBB 
disruption following stroke remains to be investigated. 
 
1.3.1.5 Astrocytes 
More than 99% of the surface of the brain capillaries is enveloped by astrocytic foot 
processes, which allow communication between endothelial cells, neurons, and pericytes. 
Many of the factors released by astrocytes (e.g. growth factors, cytokines, extracellular 
matrix proteins) are able to induce specific features of the BBB in brain endothelium, which 
are required during BBB development.366 Perivascular glial endfeet contribute to ionic, amino 
acid, neurotransmitters, and water homeostasis at the BBB level.369 A close relationship 
exists between the BBB and astrocyte membrane channel (aquaporin-4, AQP4). AQP4 
dysregulation is coupled with BBB dysfunction and edema formation.370 However, 
consequences of focal cerebral ischemia in AQP4 knockout mice are conflicting.371, 372 After 
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mild ischemia post-stroke brain swelling is not influenced by the lack of AQP4, but mice 
score worse than their wild-type littermates.372 In contrast, after permanent ischemia swelling 
and neurological scores are improved in AQP4 knockout mice.371  
 
1.3.2 Methods to evaluate BBB permeability 
The history of BBBP quantification stretches back at least 50 years.373 Currently, BBBP 
studies utilize two main methods: in vitro analysis or in vivo imaging of an extravasated 
exogenous tracer. Tracers can be classified into two categories: indicators for solute and ion 
permeability and indicators for protein permeability.374 The most common contrast agents, 
typically gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA, MW 550 Da), are in vivo 
imaging markers for solute and ion permeability, while Evans blue (EB) dye, which binds to 
albumin (MW ≈68 kDa), is accepted as the gold standard marker for protein permeability.375 
 
1.3.2.1 Qualitative methods 
1.3.2.1.1 Visualization of dye extravasation 
To monitor vascular protein leakage, in vivo studies most often used EB, which is an azo dye 
(MW 980 Da) binding irreversibly to plasma albumin in a 10:1 molar ratio.376 The EB-albumin 
complex extravasates from blood vessels into the surrounding tissues when the BBB is 
disrupted. Intravenously injected 2% EB in saline (intraperitoneal administration is also 
acceptable377) should circulate in the vasculature for a minimum of 30 min. Circulation times 
vary from 20 min to 24 h between experiments, however, accumulation with longer 
circulations than 30 min barely affects the results.377 Before terminating the experimental 
animal, the dye is cleared from the bloodstream by transcardiac saline perfusion. 
Macroscopically, blue-stained tissues indicate areas of BBB disruption. Red fluorescence of 
EB (excitation at 620 nm, emission at 680 nm) can be visualized with a fluorescence 
microscope or scanner. 
 
1.3.2.1.2 Visualization of contrast agent extravasation 
Intravenously injected contrast agent, of which bolus administration is preferable in 
conditions other than tumors,378 leaks into extravascular space in the presence of BBB 
disruption. Once in the extravascular space, voxels with higher concentrations of contrast 
39 
 
 
 
agent will appear bright on T1-weighted MR images due to T1 relaxation time shortening 
caused by the contrast agent. Simple visual analysis of this enhancement has been found to 
be a valuable tool to depict BBB disruption after many pathological conditions including AIS. 
Early BBB disruption visualized with MRI predicted subsequent hemorrhagic transformation 
in both experimental142, 143 and clinical settings.147, 379, 380 Although qualitative visual evidence 
of parenchymal enhancement on postcontrast T1-weighted MRI is a highly specific 
(specificity approximately 85%) predictor of hemorrhagic transformation, it is infrequent 
during the crucial hours after symptom onset and insensitive (sensitivity near 35%).381 
 
1.3.2.2 Quantitative methods 
1.3.2.2.1  Colorimetric and fluorometric methods  
The extravasated EB is extracted after the brain tissue is homogenized, centrifuged, and the 
supernatant is diluted. Homogenization can include the entire brain, ischemic hemisphere, or 
ischemic area only. Colorimetry at the absorbance of 600 to 620 nm after the subtraction of 
background (baseline absorbance between 500 and 740 nm) determines EB content within 
the limitations of the blue color. Fluorescence spectrophotometer at an excitation wavelength 
of 620 nm and an emission wavelength of 680 nm detects EB 100 times more sensitively 
than the colorimetric method.382, 383 
 
1.3.2.2.2 Autoradiographic method 
Although radiolabeled compounds enable highly sensitive measurements, safety concerns 
and the need to process tissues for scintillation counting preclude immunochemical or 
histological evaluation in the same experimental animals.384 Radiolabeled tracer is left in the 
circulation for some time (typically 10 to 30 min), when a number of arterial blood samples 
are collected. Brain samples undergo several procedures lasting over 24 h, thereafter Beta 
counting is performed in a spectrometer. Blood concentration of the radiolabel is measured 
by liquid scintillation counting. A blood-to-brain transfer ratio for the tracer is then determined 
according to an analytic method.385 14C-sucrose (MW 342 Da), 3H-sucrose (MW 341 Da), 3H-
inulin (MW 5 kDa), and 3H-aminoisobutyric acid (MW 103 Da) were often applied in 
experimental models of stroke studying BBBP.45, 344, 386, 387 
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1.3.2.2.3 Fluorescence methods 
Fluorescent-labeled tracers can be introduced intravenously; after obtaining simultaneous 
blood samples, tissue and blood concentration of fluorescent-labeled tracer can be quantified 
by a spectrofluorometer. By analyzing these data with an analytic method, as it is done in 
autoradiography analyses, BBBP to the tracer is estimated. Availability of intravital confocal 
microscopy to monitor extravasated fluorescent tracer is a substantial advantage of 
fluorescent-labeling technique.388, 389 BBBP to both proteins and solutes can be examined via 
the use of fluorescein isothiocynate-albumin (MW 67 kDa)390 and sodium fluorescein (MW 
376 Da),384 respectively. 
 
1.3.2.2.4 Other methods 
Immunohistochemical staining methods enable the detection and quantification of an 
extravasated endogenous macromolecule, such as IgG389 and albumin,391 or of blood cells, 
such as polymorphonuclear leukocytes.389 A recent technique, near-infrared optical imaging, 
provides intravital evaluation of BBBP with a higher spatial resolution than intravital confocal 
microscopy.392, 393 
 
1.3.2.2.5 Dynamic contrast-enhanced MRI (DCE-MRI) 
As mentioned previously, contrast enhancement of the brain tissue indicates BBB leakage. 
Dynamic method of permeability assessment is more sensitive to subtle T1 enhancements 
than simple postcontrast SE imaging alone, because DCE-MRI provides about several 
dozens of sampling times to characterize the enhancement, which increases conspicuity of 
low “effect-to-noise” ratio.139 
 
Determination of contrast agent concentration is a challenge that usually is solved via the 
measurement of the T1 of the tissue and the change in T1, with the assumption that the 
increase in T1 relaxation rate is proportional to the concentration of contrast agent.394 For this 
purpose, before, during, and after an intravenous bolus contrast agent, T1-weighted 
gradient-recalled echo imaging of the brain is repeated dozens of times over a course of 
several minutes. Then, one can analyze the data gathered with this DCE-MRI technique by 
one of available mathematical models,394 quantify contrast as a function of time, and estimate 
BBBP.381 In stroke animal experiments, a graphical approach to analyze DCE-MRI data, the 
Patlak plot approach,395 proved relevant in comparison to gold standard methods.142, 396, 397 
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and is increasingly used.291, 389 Clinical use of BBBP imaging with DCE-MRI and Patlak 
method is yet in its infancy, but retains promise for estimating clinical prediction of 
hemorrhagic transformation after t-PA treatment.398 A disadvantage of the BBBP MRI is the 
long acquisition time of the images, however, a recent study reported three and a half 
minutes as feasible.399 
 
1.3.3 BBB disruption in experimental stroke 
The profile of BBB disruption following transient focal cerebral ischemia is typically described 
as biphasic, referring constantly to same studies (more specifically to studies by Kuroiwa et 
al,400 Belayev et al,401 Rosenberg et al,344 and Huang et al386). These deserve a closer look 
and will be discussed in detail in Discussion. Table 1 resumes characteristic features of all 
animal studies which reported biphasic BBB disruption after focal ischemia-reperfusion 
injury. If one attempts to combine results from all these studies (Figure 4), it becomes clear 
that some agreement exists on the decreased leakage around 24 h and increased leakage 
around 48 h after reperfusion. 
 
 
Table 1 Animal studies of transient focal ischemia reporting biphasic BBB leakage  
 
BBB evaluation Evaluated 
Ischemia model Animal method time-points* Open Closed Less open More open References
Proximal MCA ligation cat EB 2, 3, 5, 72 h 0-2 h 3 h NA 5, 72  h Kuroiwa et al.
400
for 1 h qualitative
Intraluminal MCAO rat EB 0-1, 1-2, 1-3, 1-3 h 0-1 h 22-24 h 46-48 h Belayev et al.
401
 for 2 h quantitative 22-24, 46-48 h
Intraluminal MCAO rat 14C-sucrose 3, 6, 15, 24, 3 h 336 h 6, 15, 24, 48 h Rosenberg et al.
344
 for 2 h quantitative 48, 120, 336 h 120
Distal MCA ligation SHR 3H-sucrose 1.5-2 min, 1, 4, 22, 46 h 1.5-2 min NA 1, 4, 22 h 46 h Huang et al.
386
 for 2 h quantitative
Intraluminal MCAO rat EB 2, 6, 24, 48 h 6 h NA 2, 24 h 48 h Wu et al.
443
for 2 h qualitative
Intraluminal MCAO  rat CE-MRI 15 min, 3, 6, 24, 72 h 15 min-6 h NA NA 72 h Veltkamp et al.
438
 for 2 h semiquantitative
Intraluminal MCAO rat CE-MRI 4, 24, 48 h 4 h NA 24 h 48 h Pillai et al.
444 
 for 1,5 h semiquantitative
Intraluminal MCAO mouse EB 0-4, 4-8, 8-12, 4-8 h 8-12 h 16-20 h 12-16 h Klohs et al.
392
 for 1 h qualitative 12-16, 16-20 h
Intraluminal MCAO mouse NIRF imaging 4-8, 8-12, 12-16 h 4-8 h 8-12 h 12-16 h NA Klohs et al.
392 
 for 1 h qualitative
*time-points after reperfusion
BBB, blood-brain barrier; EB, Evans blue; CE-MRI, contrast-enhanced magnetic resonance imaging; MCA, middle cerebral artery; MCAO, MCA
occlusion; NA, not applicable; NIRF, near-infrared fluorescence; SHR, spontaneously hypertensive rat  
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Figure 4 Compiled BBB opening data of the studies resumed in Table 1. The ordinate is the 
BBB status. Closed circle indicates data collection at a single time-point; arrow indicates data 
collection during a period. Note accumulation of the data on specific time-points (ovals). 
 
1.3.3.1 Theories of biphasic BBB disruption 
The first phase of the biphasic permeability has been attributed to increased inflammatory 
and oxidative stress on the BBB, in conjunction with enzymatic degradation of the ECM by 
MMPs.44, 344 A synthetic MMP inhibitor blocked this initial opening, but had no effect on 
delayed aggravation of BBB leakage.344, 349 Associates of the final phase of the biphasic 
BBBP appears as angiogenesis357 and induction of MMP-3 and MMP-9 by cyclooxygenase-
2402, 403 The period between the two barrier openings, the “refractory period”, was assumed 
as a result of normalization of the BBB function due to subsiding hyperemia and re-
establishment of autoregulation.400 Alternatively, post-ischemic inhibition of pinocytotic 
transport400 and no-reflow phenomenon were used to explain the transient “closure” of the 
BBB.  
 
Some authors acknowledge a triphasic course for BBB opening, adding a hyperacute 
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opening, which occurs immediately after reperfusion and prior to above stated phases.357 
Theoretical explanation for this initial phase is opening of the BBB with passive disassembly 
of TJs due to hyperemia and closing by the following pericyte contraction, which supports the 
BBB.357 Actually, hyperemia has coincided with the first phase of opening reported by 
Kuroiwa et al.400 and Huang et al. confirmed a hyperacute opening, but found as the first 
phase of the biphasic opening.  
 
1.3.3.2 Continuous BBB disruption 
In recent years, with the increasing use of BBBP imaging in experimental stroke studies, 
accumulating data suggest that BBB leakage to contrast agents (because most commonly 
Gd-DTPA is used), thus to solute and ions, occurs in a continuous pattern. In addition, a 
review of previous studies reporting a biphasic BBB opening (Table 1) disclose that some 
studies in fact have failed to show any closure between two phases of increased BBB 
leakage, therefore they are also included in Table 2, which summarizes animal studies 
showing continuous BBB leakage after focal ischemia-reperfusion injury. 
 
 
Table 2 Animal studies of focal cerebral ischemia suggesting a continuous BBB disruption. 
 
Ischemia model Animal BBB evaluation method Evaluated time-points* References
Intraluminal MCAO rat albumin fluorescence 6, 12 , 24 h Albayrak et al.
400
 for 2 h qualitative
Proximal MCA ligation rat CE-MRI 0.5, 1.5, 2.5, 3.5, 4.5, 6 h Kastrup et al.
433
for 3 h qualitative
Intraluminal MCAO rat CE-MRI 0.5, 1.5, 2.5 h Neumann-Haefelin et al.
434
for 1 and 2.5 h qualitative
Intraluminal MCAO rat EB 2, 6, 24, 48 h Wu et al.
443
for 2 h qualitative
Intraluminal MCAO rat CE-MRI 0, 1, 4 days Lennmyr et al.
435
for 1.5 h semiquantitative 
Intraluminal MCAO rat CE-MRI 3, 5, 8, 12 h Nagel et al.
436
for 2 h semiquantitative 
Intraluminal MCAO rat CE-MRI 15 min, 3, 6, 24, 72 h Veltkamp et al.
438
for 2 h semiquantitative analysis
Intraluminal MCAO rat CE-MRI 3.5, 24, 120 h Nagel et al.
437
for 1.5 h semiquantitative analysis
Three-vessel occlusion rat DCE-MRI 1, 3, 7, 14, 21 days Lin et al.
439
for 1 h  quantitative
Intraluminal MCAO rat CE-MRI 4, 28, 48 h Pillai et al.
444
for 1.5 h semiquantitative analysis
*time-points after reperfusion
BBB, blood-brain barrier; CE-MRI, contrast-enhanced magnetic resonance imaging; MCA, middle cerebral artery; MCAO, MCA occlusion  
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1.4 BRAIN ISCHEMIA AND STANNIOCALCIN 
Stanniocalcin (STC) is a glycoprotein originally discovered in bony fish, in which it acts as a 
calcium/phosphate regulating hormone.404 In human, two members of STC homologs were 
discovered: STC1, which shares about 72% amino acid sequence and 80% protein similarity 
to fish405 and STC2, with approximately 34% identity and 60% homology to amino acid 
sequences to STC1.406 STCs are made in virtually all tissues and regulate various biological 
functions. Based on their ubiquitous expression patterns and generally undetectable levels in 
blood serum, it is unlikely that the mammalian STCs play important roles in serum Ca2+/Pi 
homeostasis.407 Accumulating evidence denote the involvement of STC1 and STC2 in the 
subcellular functions of mitochondria and endoplasmic reticulum, respectively, particularly 
responding to oxidative stress and unfolded protein response.407-411 
 
STCs are widely expressed in brain neurons, in choroid plexus epithelium, and to some 
degree in microvascular endothelial cells.412-415 Considerable data suggest a neuroprotective 
role for STCs. Pathological events, such as focal ischemia,416 traumatic injury,417 focal 
cryoinjury,418 and hypoxia418 increase brain levels of STC1. Overexpression of STC1 was 
linked to expression of interleukin 6 (IL-6)418 and increased neuronal resistance to hypoxia 
and hypercalcemia in vivo.416 Enhanced brain expression of STC2 followed focal brain 
ischemia and hypoxia.411 Intracerebroventricular injection of STC2 protected hippocampal 
neurons from kainic acid toxicity.419 
 
There exist no previous data regarding STCs and the BBB. Some STC1 staining was 
observed in brain endothelial cells lining the capillaries.413 In studies of angiogenesis, STC1 
upregulation is a striking finding in endothelial cells.420 A role for STC1 in maintaining 
permeability in human coronary artery endothelial cells emerged during cardiovascular 
inflammation.421 In vivo hypoxia induced, among others, STC genes in vascular endothelial 
cells.422 In human brain microvascular endothelial cells, β-amyloid peptide toxicity induces 
considerable STC-1 gene expression, which possibly exerted some antiinflammatory and 
antiapoptotic effects.414 
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2 AIMS OF THE STUDY 
 
 
1. To critically address the presumed biphasic BBB opening following transient focal cerebral 
ischemia by a systematic, quantitative, and multimodal approach. (I) 
 
2. To compare the gold standard ex vivo method of BBBP evaluation (quantification of 
extravasated Evans blue dye) to an in vivo method (DCE-MRI), that may be applicable to 
humans. (I,II) 
 
3. To compare BBBP to a large (Evans blue-albumin, MW ≈68 kDa) and small molecule 
(contrast agent Gd-DTPA, MW 550 Da). (I,II) 
 
4. To characterize spatial features of BBB leakage within the ischemic area and to find any 
correlation between the extent or severity of ischemia and the degree of BBB leakage. (I,II) 
 
5. To extend the findings from studies I and II with a more powerful study design, that 
included repeated evaluations of post-ischemic BBBP in the same animals. (III) 
 
6. Using genetically modified STC-1 deficient mice in the scenario of transient focal ischemia 
with and without prior HPC, to test the necessity of STC-1 for HPC to occur; additionally, to 
uncover the effect of STC-1 deficiency on BBBP. (IV) 
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3 MATERIALS AND METHODS 
 
 
All experiments were carried out in Biomedicum Helsinki on the premises of Department of 
Neurology, Helsinki University Central Hospital. The Animal Research Committee approved 
all studies.  
 
3.1 ANIMALS 
Adult male Wistar rats (Harlan Nederland, Horst, The Netherlands), weighing 290 to 340 g 
(I,II, and III) and adult male STC1 knockout (STC1-/-) mice on a C57BL/6 background 
(courtesy of Dr. Andy C.-M. Chang, Children's Medical Research Institute, Parkville, 
Australia) with NMRI (Harlan Nederland, Horst, The Netherlands) wild-type controls weighing 
25 to 40g (IV) were used. Previous characterization of the STC1-/- mice revealed normal 
viability and fertility and no gross histological or morphological abnormality.423 Prior to 
surgery, rats were housed in groups of five and mice in groups of 10 and after the surgery 
individually, in a temperature- and humidity-controlled environment and 12/12 h light/dark 
cycle with free access to food and water. All efforts were made to minimize animal distress 
and to reduce the number of animals used. 
 
3.2 ANESTHESIA 
Rats received an intraperitoneal injection of ketamine hydrochloride (50 mg/kg, Ketalar, 
Parke-Davis, Detroit, MI, USA) and a subcutaneous injection of medetomidine 
hydrochloride (0.5 mg/kg, Domitor, Orion, Espoo, Finland). Mice received same drugs, but 
subcutaneously. 
 
3.3 MONITORING OF PHYSIOLOGICAL PARAMETERS 
In rats, arterial blood pressure monitoring (Olli Blood Pressure Meter 533, Kone, Espoo, 
Finland) required left femoral artery catheterization by a PE-50 polyethylene tube. Left 
femoral vein catheter served for injections of contrast agent Gd-DTPA (1mL/kg, Magnevist, 
0.5 mmol/mL, Schering, Germany) (I, II, and III) and EB dye (3 mL/kg of 2% solution; 20 
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mg/mL dissolved in 1% albumin, Sigma-Aldrich, Steinheim, Germany) (I). Catheters were 
removed after reperfusion, except in Study III the femoral vein catheter was kept in place for 
one week. Rectal temperature was monitored and maintained at the physiological ranges 
with a heating blanket during the surgery and MRI. 
 
 
3.4 STUDY DESIGNS 
 
 
 
 
 
Figure 5 Schematic presentation of study designs of Study I, II, and III. Rats (overall 123) 
with adequate ischemia/reperfusion were allocated to 15 study groups based on the post-
reperfusion interval (I,II). Study III included repeated MRI of the same animals  at 5 time-
points after reperfusion and MRI protocol was identical to that of Study II, except it included 
additionally pre- and postcontrast FLAIR images. 
DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion-recovery; Gd-DTPA, 
gadolinium diethylenetriaminepentaacetic acid; IR-FLASH, inversion recovery snapshot-fast 
low-angled shot; LDF, laser-Doppler flowmetry; tMCAO, transient middle cerebral artery 
occlusion. 
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Figure 6 Schematic presentation of study design of Study IV. Each row of the schema 
resumes a separate experiment, which included two groups of mice: Wild-type and 
stanniocalcin knockout mice. Coll, collection; EB inj, Evans blue injection; HPC, hypoxic 
preconditioning; Neurol eva, neurological evaluation; tMCAO, transient middle cerebral artery 
occlusion. 
 
3.5 FOCAL CEREBRAL ISCHEMIA MODEL 
Intraluminal suture occlusion of the right MCA induced focal cerebral ischemia.274 Rat 
occluders were prepared from 4-0 nylon monofilament suture (Ethilon Nylon Suture, 
ETHICON Inc., Somerville, NJ, USA) with its tip rounded by heating near a soldering iron and 
then coated with low viscous silicone (Provil L, Bayer Dental, Leverkusen, Germany) to a 
0.38 to 0.40 mm diameter. Under general anesthesia and the rat lying on its back, the 
common carotid artery and external carotid artery were exposed through a ventral midline 
neck incision. The proximal common carotid artery and the origin of the external carotid 
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artery were ligated. The occluder was inserted into the common carotid artery via an 
arteriotomy and was advanced into the internal carotid artery approximately 17 mm above 
the carotid artery bifurcation. At this point, a mild resistance indicated that the tip of the 
occluder was lodged into the proximal anterior cerebral artery and occluded the origins of the 
MCA and the posterior communicating artery.  
 
Mouse model was slightly different.424 Mouse occluders were prepared from 5.0 
monofilament nylon suture (Ethilon Nylon Suture, ETHICON Inc., Somerville, NJ, USA) with 
their tips rounded to 0.15 to 0.20 mm diameter. Occluder was inserted into the internal 
carotid artery through an arteriotomy made in the external carotid artery. Insertion length 
from common carotid artery bifurcation was approximately 9 mm. The ligature of the common 
carotid artery was released after MCAO. Reperfusion was accomplished by withdrawing the 
suture occluder 90 min (I, II, and III) 
or 60 min (IV) after MCAO. Sham-operated animals underwent the same surgery, except 
that the suture occluder was withdrawn before causing MCAO. 
 
3.6 HYPOXIC PRECONDITIONING 
Mice (6-8 per procedure) received hypoxia in an airtight transparent low-oxygenation 
chamber perfused with 8% vol/vol oxygen in nitrogen for six hours.418 During hypoxic 
treatment mice exhibited reduced locomotor activity, which was normalized within minutes 
after returning to normal environment.  
 
3.7 LASER-DOPPLER FLOWMETRY 
CBF was measured in all animals with LDF (OxyFlo, Oxford Optronix Instruments, Oxford, 
UK) by applying a flexible fiber-optic probe. The scalp was incised in the midline exposing 
the skull. In rats, the skull area over the ipsilateral MCA region (1.0-2.5 mm caudal and 6.0 
mm lateral from the bregma) was thinned by a dental drill to allow measurement via the 
probe. In mice, without drilling, the probe was located over the territory supplied by the MCA 
(2 mm caudal and 3-4 mm lateral from the bregma). CBF was repeatedly measured before 
and during MCAO as well as after reperfusion. 
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3.8 MRI STUDIES 
MRI studies were performed with a 4.7 T scanner (PharmaScan, Bruker BioSpin, Ettlingen, 
Germany) using a 90-mm shielded gradient capable of producing a maximum gradient 
amplitude of 300 mT/m with an 80-μs rise time. The linear birdcage RF coil used had an 
inner diameter of 38 mm. Following shimming, a pilot imaging sequence (a multi-slice spin-
echo pulse sequence with repetition time/echo time: 200/8.9 ms, matrix size: 128Χ128, field-
of-view: 5.0 cm, number of averages: 1, slice thickness: 2 mm) served for reproducible 
positioning of the animal in the magnet at different MRI sessions. DWI scans were acquired 
using a spin-echo echo-planar imaging sequence (repetition time/ echo time: 4000/80 ms, 
matrix size: 128x128, field-of-view: 40x40 mm, slice thickness: 2 mm) with three b values 
(b0: 0.4, b1: 1280, and b2: 2342 s/mm2, diffusion was measured in the read gradient 
direction). Longitudinal relaxation time (T1 value) measurements were obtained with an 
inversion recovery snapshot-fast low-angled shot (IR-FLASH) sequence (repetition time/ 
echo time: 2.2/1.4 ms, 12 inversion delays from 140 to 3230 ms, flip angle: 5°, matrix size: 
128×128, field-of-view: 40×40 mm, slice thickness: 2 mm, number of averages: 15). FLAIR 
images were acquired with rapid acquisition with relaxation enhancement sequence 
(repetition time/echo time: 10,000/38.6 ms, inversion time: 1800 ms, matrix size: 256×128, 
zerofilled to 256×256, field-of-view: 40×40 mm, echo train length: 16, number of averages: 1, 
slice thickness: 2 mm). 
 
During imaging, rectal temperature was maintained at the physiological ranges by use of a 
MRI compatible heating pad and pump (Gaymar Industries, Orchard Park, NY, USA). 
 
During DWI, a 7-slice data set was obtained covering the entire brain except the olfactory 
bulb. The first axial slice was selected posterior to the olfactory bulb, navigating by the rhinal 
sulcus detected on the pilot image, and the following slices were placed caudally at 2-mm 
intervals. Images of IR-FLASH and FLAIR were obtained with a single axial slice at the 
coordinate of the third slice of the DWI, the optic chiasmal slice, which is approximately at 0.5 
mm posterior to the bregma. All the analyses, except ischemic volume calculation, were 
performed on this slice. The IR-FLASH scan with inversion delay −1826 ms was chosen as 
the T1-weighted image (T1-WI). The DWI scan with b0 provided the T2-weighted image (T2-
WI). T1 maps were constructed from each IR-FLASH sequence and apparent diffusion 
coefficient (ADC) maps from DWI sequences using ParaVision 2.1.1. Software (Bruker 
BioSpin, Ettlingen, Germany). All image analyses described below used ParaVision 2.1.1. 
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Software. Regions of interest (ROIs) were placed manually on the ipsilateral hemisphere and 
control ROIs were placed on the homologous locations in the contralateral hemisphere 
(Figure 7). 
 
 
 
Figure 7 Regions of interest (ROIs). A, from Study II and B, from Study III. 
 
3.8.1 Patlak plotting 
Patlak plotting395 is a graphical analysis method of the plasma and tissue MRI data, to 
estimate the blood-to-brain transfer rate constant of the contrast agent (Ki) in the 
permeability-limited circumstances of a two-compartmental model, such as focal brain 
ischemia. It is assumed that there is a steady phase in the blood-to-brain distribution of the 
tracer during which the tracer crosses the BBB in one-way direction, towards the brain tissue. 
If plasma and tissue MRI data, which are collected repeatedly overtime, are plotted, this 
results in an uptake curve with a linear phase of which the slope approximates Ki.  
 
To make the Patlak plots, arterial plasma and tissue concentration of contrast agent (Gd-
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DTPA) are needed. Intravenous administration of Gd-DTPA leads to a change in reverse 
longitudinal relaxation rates (R1) of protons in its distribution area. With the assumptions that 
1) the increase in relaxation rate (∆R1) is proportional to the concentration of contrast 
agent394 and 2) tissue relaxivity (r1t) and plasma relaxivity (r1p) are the same,327 following 
equation is acquired:  
 
R1t(t) = R1t(t)-R1t0(t) = r1tCt(t) and R1p(t) = R1p(t)-R1p0(t) = r1pCp(t) (1-Hct) 
 
where (t) is the duration of the experiment, R1t0(t) is the tissue longitudinal relaxation rate 
before Gd-DTPA injection and R1t(t) at the end of experiment; R1p0(t) is the plasma 
longitudinal relaxation rate prior to Gd-DTPA injection, and R1p(t), at the end of the 
experiment; Ct(t) is the tissue concentration of the Gd- DTPA at the end of the experiment; 
Cp(t) is the plasma concentration of GD-DTPA at the end of the experiment; Hct is the 
hematocrit (arbitrarily 43%). Cp of Gd-DTPA was measured from the superior sagittal sinus. 
This approach of approximating arterial input function of the tracer in arterial blood through 
measurements from venous system has no significant affect on Ki results.425 
 
Accordingly, the relation between tissue and plasma concentrations of Gd-DTPA is described 
in the following equation: 
Ct(t) = Vp Cp (t)  +  Ki  
t
0
 Cp (τ) dτ 
where Cp (T) is the plasma concentration at a series of times over the duration of the 
experiment and is used to calculate the arterial-concentration time integral; Ki is the blood-to-
brain transfer rate constant of Gd-DTPA; Vp is the blood plasma volume. 
Patlak plots are constructed by plotting Ct(t) / Cp(t) (ordinate) versus 
t
0
 Cp (τ) dτ / Cp (t) 
(abscissa). The abscissa has the units of time, which is not the real time but the 
concentration-adjusted time (tstretch). (Figure 8) 
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Figure 8 Patlak plots of a representative rat. Imaging was performed at 2 hours after 
reperfusion that followed 90-min ischemia. The ordinate is the ratio of brain tissue 
concentration of Gd-DTPA to its plasma concentration. The abscissa represents 
concentration-adjusted time, stretch time. Plotted data showed linearity during whole imaging 
time (20 to 30 min). 
 
3.8.2 Imaging protocol 
All rats underwent DWI to ensure the presence of stroke immediately after induction of 
MCAO confirmed by LDF. Sham animals underwent MRI 24 h after sham operation, 
otherwise MRI was run at the corresponding time-points after reperfusion (see Study design). 
MRI protocol included: a pilot sequence, DWI, a pair of IR-FLASH sequence, and a post-
contrast IR-FLASH sequence 25 min following a bolus of Gd-DTPA injection (I) or 
repeated IR-FLASH sequences at approximately 1-min intervals for 20 to 30 min after Gd-
DTPA injection (II, III) and pre- and post-contrast FLAIR sequences (III). MR imaging took 25 
to 35 min.  
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3.9 NEUROLOGICAL EVALUATION  
Sensorimotor performance of mice was scored 24 hours after reperfusion (IV), as follows: 
0, normal; 1, contralateral paw paralysis; 2, contralateral paw paralysis plus decreased 
resistance to lateral push; 3, 2 plus circulating behavior; 4, no spontaneous walking with 
depressed consciousness; and 5, death.426 
 
3.10 TISSUE HANDLING 
After various periods of time following reperfusion (see Study design), animals were 
reanesthetized with a lethal dose of intraperitoneal pentobarbital (1 mL/rat, 0.04 mL/mouse, 
Mebunat, 60 mg/mL, Orion). For cardiac perfusion, after a midline abdominal incision, the 
chest was opened. A catheter was inserted into the aorta via the left ventricle and ice cold 
0.9% saline (200 mL for rats and 30 mL for mice) was infused into the aorta at approximately 
100 mmHg pressure. The blood drained out via an incision made to the right atrium. The 
brains then were quickly collected and dissected into six 2-mm-thick (1-mm-thick in mice) 
coronal slices for digital imaging (Sony, Tokyo, Japan). Every 3rd slice was cut into two 
halves coronally (rostral and caudal). The rostral part was embedded in Tissue-Tek (Sakura 
Finetek Inc., Tokyo, Japan), snapfrozen in liquid nitrogen, and kept thereafter at 80 °C until 
15-µm of sections were cut for analysis of EB-albumin extravasation (I) and 150-µm sections 
were cut for mRNA analysis (IV). All the remaining slices were stained with 0.2% TTC at 37 
°C (IV) and immersion-fixed in 10% formaldehyde. 
 
3.11 ISCHEMIC LESION ASSESSMENT 
3.11.1 MRI-based infarction 
At acute time-points (<72 h) DWI and otherwise T2-WI were used to calculate the area or 
volume of the ischemic lesion. Regions with increased signal intensity (restricted diffusion in 
DWI and increased water content in T2-WI) were manually outlined. Area calculation was 
based on the optic chiasmal slice, where ischemia involved both cortex and subcortex 
(Figure 9). Lesion areas from all slices were summed up and multiplied by slice thickness, 
yielding the uncorrected lesion volume. Afterwards, the volumetric difference between the 
right and left hemisphere (due to swelling) was subtracted from the uncorrected lesion 
volume, yielding the (edema) corrected lesion volume.  
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Figure 9 Ischemic lesion delineation. On the left is magnetic resonance imaging (MRI) 
diffusion weighted image (DWI) taken 2 h after 90-min ischemia. On the right is digital 
pictures of TTC-stained brain slices of a mouse subjected to 60-min ischemia. TTC, 2,3,5-
triphenyltetrazolium chloride. 
 
3.11.2 TTC-based infarction 
TTC-stained brain slices were photographed with a digital camera (Figure 9) and images 
were analyzed using NIH software Image J.427 In each slice, unstained ischemic tissue, 
presented as pale areas, was manually outlined. As described above, uncorrected and 
edema-corrected lesion volumes were calculated.274 Lesions were reported as the 
percentage of the intact hemisphere (% hemispheric lesion volume). The percentage of 
edema was also reported relative to intact hemisphere. 
 
3.12 BLOOD-BRAIN BARRIER PERMEABILITY ASSESSMENTS 
3.12.1 Evans blue extravasation 
Rats received intravenously (I) and mice retro-orbitally (IV) a dose of EB (3 mL/kg for rats 
and 1mL/kg for mice of 2% solution; 20 mg/mL dissolved in 1% albumin, Sigma-Aldrich, 
Steinheim, Germany) 20 to 25 min before collecting the brains.  
 
Evans blue fluorescence signal intensity (I and IV) and the area of EBA extravasation (I) 
were measured with a fluorescence scanner (Typhoon 9400, Amersham Biosciences, 
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Buckinghamshire, UK).428 In Study I, the area of EB extravasation was manually outlined and 
the average fluorescence signal intensity within this area and of the intact hemisphere was 
measured. In Study IV, because, if any, a widespread BBB leakage was expected, EB 
fluorescence was calculated as the ratio of the average signal intensity of the whole brain 
specimen to signal intensity of a reference point out of the hemisphere with the image 
analyzer software ImageQuant (Amersham Biosciences Buckinghamshire, UK). 
 
3.12.2 Contrast-enhanced MRI 
3.12.2.1 Percentage of enhancement of the ischemic lesion  
The enhancement area on postcontrast T1-weighted image represents the area of BBB 
leakage. Contrast enhancement area was manually outlined (I, III) and by taking its ratio to 
the lesion area and multiplying by 100 the percentage of enhanced ischemic lesion (% Gd-
DTPA) was calculated.  
 
3.12.2.2 Contrast-to-noise ratio of the enhancement area  
Signal intensities (I) were collected from manually outlined enhancement area (Sinf), the 
entire contralateral hemisphere (Snormal), and a reference point outside the brain tissue 
(noise). Thereafter, signal intensity of the nonischemic hemisphere was subtracted from the 
signal intensity of the enhancement area and the ratio to the noise was calculated yielding 
contrast-to-noise ratio of the enhancement ((Sinf-Snormal)/noise). 
 
3.12.2.3 Signal intensity change due to enhancement  
Signal intensity values were collected (III) from the enhancement area on the postcontrast 
T1-weighted image (SIpost) and from the corresponding area on the precontrast T1-weighted 
image (SIpre). Signal intensity change due to Gd-DTPA enhancement was calculated by 
substracting SIpre from SIpost and by taking its ratio to SIpre and multiplying by 100 
((SIpost−SIpre)/SIpre×100).  
 
3.12.2.4 The blood-to-brain transfer constant of Gd-DTPA  
ROIs were manually placed (II, III) in the ischemic hemisphere on postcontrast IR-FLASH 
scans in a standard manner (Figure 7). Arterial concentration of Gd-DTPA was estimated 
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from the superior sagittal sinus as described by others.396 Data collected from ROIs of each 
IR-FLASH sequence were fitted to calculate T1 values and afterwards inverse T1 values were 
calculated (R1). These data were further applied to Patlak plot equations396, 429 as described 
above, yielding as slope the blood-to-brain transfer constant of Gd-DTPA (Ki), which is an 
estimated measure of BBBP to Gd-DTPA. 
 
3.13 QUANTITATIVE ANALYSES OF    
From pooled brain slices of ischemic mice (IV), total RNA was isolated by use of TRIZOL® 
Reagent (Invitrogen, Carlsbad, CA, USA). The High Capacity RNA-to-cDNA Kit (Applied 
Biosystems, Foster City, CA, USA) was used to prepare cDNA and quantitative real-time 
PCR was performed with the LightCycler® II instrument (Roche Diagnostics, Mannheim, 
Germany) and the Maxima SYBR Green qPCR Master Mix (2X) (Fermentas, Vilnius, 
Lithuania). Primers were: Stc1; 5’-ATGCTCCAAAACTCAGCAGTGATTC-3’ and 5’-
CAGGCTTCGGACAAGTCTGT-3’, Stc2; 5’-GCATGACGTTTCTGCACAAC and 5’-
CAGGTTCACAAGGTCCACAT, and Il-6 5’-CTTCCCTACTTCACAAGTCC-3’ and 5’-
GCCACTCCTTCTGTGACTC-3’. Stc1, Stc2, and Il-6 mRNA levels were normalized against 
levels of beta-2-microglobulin, of which primers were: 5’-GCTATCCAGAAAACCCCTCA-3’ 
and 5’-ATGTCTCGATCCCAGTAGAC-3’. All primers were from Proligo LLC, Paris, France. 
 
3.14 STATISTICAL ANALYSES 
All parametric data are presented as mean ± SD. Normally distributed parametric data sets 
were analyzed with Student’s t-test (two groups) or one-way ANOVA followed by Holm-Sidak 
post hoc test (multiple groups). When normality failed, Kruskal–Wallis test followed by Dunn's 
method assessed differences between multiple groups. Nonparametric data (neurological 
scores) from two groups were analyzed by the Mann-Whitney U test. Repeated measures of 
ANOVA followed by Holm-Sidak post hoc test examined the temporal differences of an 
individual parameter. Paired t-test was used to study differences between data sets from the 
same animal. MRI data of the superior sagittal sinus were fitted to an exponential curve. 
Linear regression analysis of each MRI data set, which was obtained from the ROIs of T1 
maps, yielded as slope the blood to brain transfer rate constant of Gd-DTPA, Ki. Spearman 
correlation coefficient analysis served to identify correlations. A two-tailed value of P < 0.05 
was considered significant. 
Stc1, Stc2, and Il-6 mRNA 
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4 RESULTS 
 
 
Study I and II 
These studies included a comprehensive evaluation of the BBBP following transient 
occlusion of the MCA in rats. Encompassing all the hyperacute, acute, subacute, and chronic 
phases of the post-reperfusion period with 15 different groups of rats (2, 4, 6, 12, 18, 24, 36, 
48, and 72 h and 1, 2, 3, 4, and 5 weeks), BBBP to both large and small molecules were 
quantitatively characterized, the former via the gold standard method (Evans blue 
fluorescence) and the latter with gadolinium-enhanced MRI. 
 
Animals 
After the exclusions due to premature death and subarachnoid hemorrhage, 123 rats (N=6-8 
per group) completed the experimental period. Control animals included eight sham-operated 
rats. No significant differences arose in the physiologic parameters (mean arterial blood 
pressure and temperature) between study groups. 
 
Ischemic lesions 
In all animals successful MCAO and reperfusion were ascertained with LDF, which showed a 
mean CBF value 14% (±3) of the baseline during occlusion and after reperfusion 65% (±4) of 
the baseline. Ischemic lesions were visualized immediately after occlusion with DWI 
sequence of MRI, revealing substantial-sized cortico-subcortical lesions. Final infarct 
volumes at the corresponding time-points were similar among groups (in average 0.22±0.10 
cm3, P=0.42). Volumes were in good correlation with lesion areas (r=0.710, P=0.003) 
calculated from the optic-chiasmal slice, which was used for BBBP quantifications. Control 
animals were free of ischemic lesions. 
 
BBB leakage to Evans blue 
EB fluorescence quantification indicated that at all time-points, except for 3 and 5 weeks after 
reperfusion, EB extravasated into ischemic area (P<0.001), with a slight decrease at 36 and 
72 h. 
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BBB leakage to Gd-DTPA 
Gd-DTPA presence in the ischemic parenchyma led to increased contrast-to-noise ratio in 
the post-contrast T1-weighted images at all time-points, except for 5 weeks. This increase 
was slightly lesser at the earliest time-point (25 min) of the study and at the two latest time-
points (3 and 4 weeks) of Gd-DTPA leakage. 
 
GD-DTPA leakage estimated as blood-to-brain transfer constant (Ki) via Patlak plotting of 
DCE-MRI data, indicated a sustained leakage up to 5 weeks after reperfusion (P<0.001).  
 
Spatial pattern of BBB leakage 
BBB leakage to both tracers were limited to ischemic area, but the extent of the leakage 
varied depending on the time-point and the tracer, though always being smaller than the 
extent of the ischemic lesion (49-90% of the ischemic lesion)(Figure 10). Starting from 72 h, 
EB leaking area was smaller than Gd-DTPA leaking area (P<0.01). 
 
Figure 10 Leaking lesion areas. The size of Evans blue (EB) and contrast agent (Gd-DTPA) 
leaking areas are compared (**, P<0.01). 
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Parameters affecting BBB leakage 
The severity of the ischemia extrapolated from ADC values correlated with the degree of 
ischemia (r=-0.58, P=0.02), the lower the ADC value, the higher the blood-to-brain transfer 
constant of Gd-DTPA. The extent of the ischemic lesion was another factor associated with 
increased BBB leakage to Gd-DTPA (r=0.75, P=0.0015), larger lesions depicted a more 
leaky BBB with higher Ki values. Ki values showed a trend of decrease overtime (r=-0.61, 
P=0.01). 
 
Study III 
Appreciating the large standard deviations in BBBP related parameters obtained in previous 
studies, this study was designed to diminish inter-animal variability and to test more 
vigorously the hypothesis of continuous BBB leakage following transient ischemia. Study 
included the same animal model as in the previous studies, and DCE-MRI was repeated at 5 
time-points after reperfusion (2, 24, 48, and 72 h and 1 week). Signal intensity analysis and 
Patlak plotting of MRI data allowed estimating BBBP to Gd-DTPA. 
 
Ten rats with successful MCAO and reperfusion as documented by laser-Doppler 
flowmetry and six sham-operated control animals were included in the study. No significant 
differences emerged in physiological parameters (mean arterial blood pressure, 
temperature) among animals or time-points. Baseline ischemic lesions calculated from DW 
images were similar among animals (P=0.971). Uncorrected ischemic lesion volumes 
increased between 2 h and 24 h and decreased thereafter, reflecting formation and 
resolution of edema, respectively. A good correlation appeared between lesion volumes and 
areas (r=0.767, P<0.001) calculated from the optic-chiasmal slice, which was used for BBBP 
quantifications. Sham animals showed no brain pathology. 
 
The Gd-DTPA leakage, analyzed as signal intensity change from post-contrast T1-
weighted images relative to precontrast images, was higher than that of shams at all time-
points (P<0.001, ANOVA), indicating a continuous leakage. Among time-points, 1 week was 
associated with higher signal intensity change (P<0.001, RM-ANOVA) (Figure 11). 
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Figure 11 Monitoring of ischemic lesion and blood-brain barrier (BBB) disruption by magnetic 
resonance imaging (MRI) in a representative rat. Gray scale MRI images are diffusion 
images (starting from 48 h with b0, which provides T2-weighted image), colored images are 
color-coded post-contrast fluid attenuated inversion recovery images. There is continuous 
leakage into ischemic area, which is most pronounced at 1 week. See color scale bar for 
increasing gadolinium (Gd) leakage. 
 
A second method for estimating BBBP to Gd-DTPA used Patlak plotting of the DCE-MRI 
data, which provided blood-to-brain transfer constant of Gd-DTPA, Ki. With the knowledge of 
heterogeneity within the ischemic lesion, data collection applied two methods. Firstly, cortical 
and subcortical parts of the ischemic lesion were analyzed as entireties, and secondly small 
circular ROIs (3 per cortex and subcortex) provided the data (Figure 7B). With the first 
approach, neither cortical, nor subcortical Ki values differed among time-points (P>0.05, RM-
ANOVA), being different than those of sham animals and of contralateral values during the 
whole experiment (P<0.005, ANOVA). With the second approach, a difference in Ki values 
among time-points appeared only in the comparison of values from a cortical ROI (ROI-c2, 
Figure 7B). 
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Study IV 
This study explored the role of STC-1 in HPC and in the BBB integrity via the use of 
genetically modified STC-1 deficient (STC-1-/-) mice. Transient (60 min) occlusion of the MCA 
was introduced to STC-1-/- mice and wild type (WT) littermates, with or without HPC (6 h of 
8% oxygenation), 24 h prior to ischemia. BBB experiments assessed EB fluorescence in 
STC-1-/- mice and WT mice under normal conditions, and immediately and 24 h after hypoxia. 
Real time polymerase chain reaction quantified Stc-1, Stc-2, and Il-6 mRNA with DNA 
extracted from ischemic brains.  
 
After the exclusions due to subarachnoid hemorrhage, inadequate occlusion or reperfusion, 
and premature death, HPC experiments included nine to ten mice per group. 28 mice were 
subjected to BBB experiments (N=4-5 per group). No differences existed in body weights or 
rectal temperatures of the animals. In HPC experiments, LDF measurements ensured similar 
rates of CBF reduction during MCAO (P=0.105) and of CBF recovery after reperfusion 
(P=0.118). 
 
In STC-1-/- mice and WT mice, HPC prior to ischemia resumed in equally smaller infarctions 
than did ischemia only (22±10% vs. 26±8%, P=0.336). In both scenarios, STC-1-/- mice 
exhibited worse neurological scores than of WT mice, although HPC improved neurological 
outcome of ischemia in STC-1-/- mice (P=0.024, Figure 12). 
 
When HPC was introduced prior to ischemia, brain mRNA expressions of Stc1 (P=0.005) 
and Stc2 (P=0.035) in WT mice and of Stc2 in STC-1-/- mice (P=0.002) were increased 
compared to ischemia only. After ischemia only, brain Il-6 mRNA levels differed between 
STC-1-/- and WT mice (P=0.033), with 9-time lower levels in STC-1-/- mice. 
 
EB fluorescence results were comparable between STC-1-/- and WT mice under normal 
conditions (P>0.05) and the application of hypoxia did not result in increased leakage in STC-
/- mice neither immediately (P>0.05), nor 24 h after hypoxia (P>0.05). 
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Figure 12 Distribution of neurological scores. STC knockout mice (STC-/-) and wild type (WT) 
mice were subjected to 60-min ischemia; STC-/--HPC and WT-HPC mice received hypoxic 
preconditioning (HPC) 24 h before ischemia. N=9 to 10 per group. 
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5 DISCUSSION  
 
 
Stroke, the second leading cause of death worldwide,430 will affect approximately one of 
every six persons,431 leaving each year 5 million people dependent on others.2 Ischemic 
stroke is responsible nearly 80% of all strokes and occurs due to occlusion of a cerebral 
artery. Consequently, brain region supplied by the occluded artery is left without blood flow 
and undergoes complex pathophysiological events that cause irreversible damage, unless 
timely reperfusion occurs. Early reperfusion (spontaneously or therapeutically) is beneficial 
and limits the injury, but late reperfusion exacerbates the injury through further harmful 
events. Among these, BBB disruption is the most critical. 
 
The BBB protects central nervous system against harmful ingredients of the circulating 
blood, first as a physical barrier through its structural components, second as a functional 
and selective mechanical barrier through its transport mechanisms, and finally as an 
enzymatic barrier. Accordingly, large molecules, including most proteins, drugs, and cellular 
elements of the blood, are blocked from the central nervous system under normal conditions. 
In disease conditions, such as ischemic stroke, the brain is left without this crucial guard at 
varying degrees; at the extreme, massive edema and symptomatic hemorrhagic 
transformation occurs.  
 
In animal models of transient focal cerebral ischemia (ischemic stroke with reperfusion), BBB 
disruption is long believed occurring in a biphasic pattern. This assumption however is based 
on few studies performed more than two decades ago and are still repeatedly cited.344, 386, 400, 
401 A critical analysis of these works discloses several methodological issues, which 
complicates the interpretation of their data in order to achieve a common conclusion and 
raises doubts on the so-called biphasic nature of the BBB leakage following ischemia-
reperfusion.  
 
Knowing the time course and the degree of BBB leakage following ischemia-reperfusion is 
crucially important in AIS patients for several reasons. First, patients at higher risk of 
experiencing the devastating consequences of severely leaking BBB (massive edema and 
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symptomatic hemorrhagic transformation) could be detected early; second, candidate 
regimens to prevent or alleviate these harmful effects could be introduced within a correct 
therapeutic window, presumably early in the acute phase; third, in the later phases, when 
repair mechanims take place, it enables offering the brain drugs for enhancing these 
beneficial mechanisms (i.e. neurorestoration). If the BBB ceases to leak, potential drugs of 
neuroprotection or neurorestoration would not reach the brain.  
 
Biphasic BBB leakage was originally defined by Kuroiwa et al.400 as an earlier leakage 
followed by a non-leaking state and a second leakage. Authors400 have applied transorbital 
occlusion of the MCA to cats and they have provided detailed data on CBF values. However, 
infarct sizes are missing. It is known that this ischemia model is associated with variable 
outcomes.432 Only four groups of animals (for EB evaluations at 2, 3, 5 and 72 h after 
reperfusion) were studied, with 6 to 11 cats per group. First group received EB injection 
immediately after reperfusion and EB stayed in the circulation for two hours. In other groups, 
EB was left to circulate for 30 min. BBB leakage was visually analyzed, which is the weakest 
feature of the study. In all groups, except in 3 h group, EB was observed in ischemic areas. 
These cats (N=11) without EB leakage however showed serum protein leakage, and this was 
interpreted as the result of the first barrier opening, which occurred during zero to two hours 
after reperfusion. They explained the lack of EB leakage (“refractory period”) with two 
contradictory theories: Either BBB functions were fully recovered or were severely disturbed, 
that EB transport through the BBB into central nervous system was inhibited.  
 
Two following studies reporting biphasic BBB leakage, one by Belayev et al.401 and the other 
by Rosenberg et al.,344 fortunately used the same stroke model (2 h ischemia with suture 
MCAO) and quantitative evaluations of BBBP, but with tracers of different sizes: EB (large 
tracer) and radiolabeled sucrose (small tracer), respectively. EB was left in the circulation for 
one or two hours and radiolabeled sucrose for 10 minutes. Although study of Belayev et al. 
did not utilize LDF-control on the ischemia, reported lesion volumes indicate that they have 
induced considerable sizes of infarctions. Rosenberg et al., on the other hand, did not 
provide any data on the CBF changes or infarctions induced. Time-points included in the 
study of Belayev et al. generally overlap with the time-points of the study by Kuroiwa et al.400 
However, at earlier time-points (0-2 h after reperfusion) when Kuroiwa et al. found the BBB 
open, Belayev et al. detected no EB leakage. Starting from one to three hours after 
reperfusion EB was leaking in the striatum at all the time-points evaluated, with maximum 
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leakage at 46 to 48 h after reperfusion. Rosenberg et al. studied a high number of time-
points, involving several time-points before 24 h (thus covered the long gap in the other 
studies386, 400, 401) and further time-points than 72 h (which were not previously studied). 
Unfortunately, the first 3 h of reperfusion, at which others were found the first BBB 
opening,386, 400 was ignored. Rosenberg et al. reported two BBB openings occurring firstly at 
3 h and secondly at 48 h after reperfusion. Although they did not comment on time-points 
between these two extremes, they reported that BBBP was returned to normal by 14 days; 
thus, one can suggest that some degree of leakage existed between 3 and 48 h post-
reperfusion.  
 
Huang et al.386 induced small cortical infarcts in spontaneously hypertensive rats using 
surgical distal MCAO for two hours. BBBP was evaluated with radiolabeled sucrose at time-
points mostly similar to those in the studies of Kuroiwa et al. and Belayev et al. The particular 
difference was in the earliest time-point, which covered the first very minutes of reperfusion. 
Huang et al. noted an increased BBBP in the neocortex at this earliest time-point that 
conflicts with the study of Belayev et al. This early BBB leakage was followed by a partial 
recovery at 1 and 4 h post-reperfusion, which was interpreted resulting from the closure of 
the BBB. Further increases in the BBBP occurred at 22 h and at 46 h (maximal increase) 
post-reperfusion.  
 
To summarize, these four most referred studies, which suggest biphasic BBB opening after 
ischemia-reperfusion, disagree on the course of biphasicity from several aspects and raise 
serious concerns. Timing of the first opening is uncertain, does it occur very early (within 
minutes) after reperfusion386 or within hours? 344, 401 Is there really any closure of the BBB 
within leaky periods,400 does it mean a complete functional recovery in the middle of ongoing 
pathologic events of ischemic cascade? Timing of presumed second opening is ambiguous 
too, does it occur as early as 5 h400 or as late as 48h after reperfusion?344, 401 Does the tracer 
size affect the results of post-ischemic BBBP? This last issue was not tested in above 
mentioned studies. 
 
Stimulated by these questions, the first three studies included in this thesis were performed. 
A well-known transient ischemia model (suture occlusion of the MCA in rats) was assisted 
with LDF and MRI to ascertain the occlusion and reperfusion, therefore to reduce outcome 
variability. BBBP changes were monitored, first with a comprehensive study protocol, which 
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included 15 groups of animals, covering all the phases of post-reperfusion and avoiding long 
gaps between time-points (I, II). Second, to confirm the findings of the first two studies with a 
more powerful study design, BBBP changes were monitored longitudinally, in a single group 
of animals (III). We quantified BBB protein permeability (via large molecule EB-albumin 
extravasation) (I) and ion permeability (via small molecule, Gd-DTPA extravasation) (I; II, and 
III), using the gold standard ex vivo technique (EB fluorescence) and a novel in vivo 
technique (contrast-enhanced MRI), respectively. 
 
The consistent finding in the results (I, II, and III) is that, BBB leakage following ischemia-
reperfusion is continuous and long-lasting, without any closure up to several weeks. 
Acknowledging the complex pathophysiological changes triggered by ischemia-reperfusion, 
where many mediators and mechanisms take place in a temporal manner, variations in the 
degree of the BBB leakage is expected. However, the biphasic BBB leakage concept is an 
oversimplification and is misleading, because it involves not only perturbations (first and 
second openings) of the leakage, but also cessation of the leakage in between perturbations 
(so-called closure of the BBB). Such closure was found to happen at a wide range of 0 to 12 
h (Table 1), which however falls into acute phase of stroke, when ischemic injury is yet 
evolving and repair mechanisms are inactive. In the studies included in this thesis (I, II, and 
III) continuity of the BBB leakage was proven for both large and small molecules and with 
both transversal and longitudinal study designs. Until the stage of an absolute lack of the 
leakage at several weeks after reperfusion, no transient closure of the BBB (in other terms, 
refractory period400) occurred. Recent MRI-based evaluations of BBBP discredit the 
assumption of biphasic BBB leakage and point towards gradually increasing leakage up to 
24 h (Table 2).433-439 Experimental data on long-term behaviors of the BBB following 
ischemia-reperfusion are scarce and inconsistent. In rats subjected to 90-min MCAO via 
suture occlusion method344 sucrose leakage (small molecule) ceased at 2 weeks. In a tree-
vessel occlusion model in rats, after 60 min ischemia, Gd-DTPA leakage continued up to 3 
weeks. Our studies (I,II) are the most comprehensive off all studies investigating BBBP after 
focal brain ischemia as we covered a wide range time-points and used both a small (Gd-
DTPA) and large molecule (EB). 
 
In vivo BBBP imaging with CT or MRI techniques detects varying rates of increased 
permeability in ischemic stroke patients (from 20 to 88%),138-140 more often in the subacute 
phase. After 3 weeks parenchymal contrast enhancement tends to decrease.440 Our 
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quantitative MRI results are in agreement with human findings, that a continuous but slowly 
decreasing permeability to contrast agent was detectable during 4 weeks after stroke. We 
should note that our MRI experiments differ from clinical MRI practice from many aspects: 
First, a high field strength MRI was used (4.7 T). Second, Gd-DTPA dose was 0.5 mmol/kg 
(a considerably high dose, 5 times higher than in usual clinical practice, that even rarely 
applied in experimental stroke437); and last, contrast-enhanced images were collected as late 
as 30 min after Gd-DTPA bolus injection (a feature that may not be feasible in AIS patients). 
All these factors improve the chance to detect even minute amounts of contrast 
enhancement. 
 
In concert with previous findings (Table 1, Figure 3), a nonsignificant decrease in BBB 
leakage occurred to both large and small tracers around 24 to 36 h (I, III). Potential 
explanation for this drop in the leakage is no-reflow phenomenon.441, 442 According to this 
concept, plugs of neutrophils can interrupt microvascular circulation early after reperfusion, 
consequently the delivery of the tracer from blood to the brain may be limited despite a 
disturbed BBB. An interesting point is that at 24h post-reperfusion while the degree of 
leakage decreases,443 the extent of leaky area increases.444 Another alteration observed was 
at 1 week, as an increased leakage (III). However, this increase was nonsignificant, when 
BBBP was evaluated encompassing the entire lesion. Only a limited cortical area was 
responsible for this trend (Figure 7B, ROI-c2). Recent data concerning post-stroke 
angiogenesis439, 445 suggest this finding of increased BBB leakage at 1 week post-reperfusion 
a proof for regeneration, rather than being related to clinical deterioration.  
 
Previous works disclosed that increasing the duration (therefore the severity) of the transient 
ischemia results in deterioration of the BBB damage.142, 433, 434, 446 In agreement with this, our 
results indicate that brain areas with lower ADC values show higher permeability and the 
larger the ischemia area is, the higher the BBBP.  
 
A growing body of data suggests increased BBBP as a predictor of hemorrhagic 
transformation.140, 141, 149-151 BBBP quantification with imaging methods in stroke is yet a 
developing area and awaits standardization based on large clinical trials. One unsolved issue 
is the consequences of varying degrees of BBBP. In theory, if the permeability of the BBB is 
not large enough for blood cellular elements to pass, hemorrhage will not occur, but BBB 
leakage to much smaller molecules such as albumin, may cause edema.152 At this context, 
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BBBP evaluations with different size of tracers are of importance. In the studies included in 
this thesis, post-ischemic BBB leakage to large and small tracers showed different temporal 
and spatial profiles. Leakage to both tracers started early after reperfusion (at 25 min), 
leakage to large molecule ceased at 3 weeks, and to small tracer at 4 weeks. When leaking 
areas were compared, at 25 min post-reperfusion, surprisingly large molecule’s leakage 
tended to be larger compared to small molecule’s leakage (P=0.063). Afterwards, up to 48 h, 
both tracers leaked to similar extents. However, from 72 h to 2 weeks EB leaking area was 
significantly smaller than contrast leaking area. Taken together, these data may suggest that 
very early BBB disturbance occurring after ischemia-reperfusion is more pronounced for 
larger molecules, but at the chronic phase BBB function recovers earlier for larger molecules. 
Tracer size depending behavior of post-ischemic BBB was also previously noted. At 3 h after 
3-hour-long transient ischemia in rats, EB extravasated into ischemic area, but red blood 
cells or dextran did not.447 At 21 h, all tree elements have leaked through the BBB. In the 
same animal model, at 21 h after reperfusion, small molecule leaking areas were two times 
larger than large molecule leaking areas, and leakage of large molecule was associated with 
higher BBBP.448 When BBB leakage to a very large molecule at 3 and 21 h post-reperfusion 
was compared spatially, same authors noticed that from 3 to 21 h leaky areas were 
increased by nearly 50%.449 Unfortunately, these authors focused on only 3 and 21 h post-
reperfusional periods. Our results on very early or late BBB behavior to different size of 
tracers require confirmation with further studies.  
 
In the studies where STC1-knockout mice were used (IV), STC1-deficiency was not 
associated with increased infarct volumes, but resulted in worse neurological scores 
compared to wild-type mice. Moderate-sized lesions (approximately 23% of the ipsilateral 
hemisphere) caused mild neurological disability in wild-type mice, but STC1-deficient mice 
with similar-sized infarcts were severely disabled or died. It is unlikely that the hemorrhagic 
transformation observed in STC1-deficient mice (3 out of 10) was alone responsible for this 
deterioration, because although hypoxic preconditioning was effective in reducing lesion size 
in these mice, they still scored worse than wild-type mice without having hemorrhagic 
transformation. We suggest that reduced expression of IL-6 (a multipotent neuroprotective 
cytokine) in ischemic brains of STC1-deficient mice may have led to increased inflammation. 
Elucidating the role of STC1 in preserving neurological functions after ischemia requires 
further studies.  
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BBB permeability in STC1-knockout mice was disturbed neither in health, nor after hypoxia. 
Although we did not examine BBBP in STC-knockout mice subjected to ischemia, we found 
no increased edema formation in these mice compared to wild-type littermates. This implies 
that STC1 has no major contribution in preserving BBB functions in health or disease.  
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6 SUMMARY AND CONCLUSIONS 
 
 
This thesis provides strong evidence that, following transient focal ischemia, BBB leakage is 
continuous (monophasic) and long-lasting. There is a transient reduction in the BBBP around 
24 h post-ischemia, but it is not closed. Hence, biphasic BBB leakage for this scenario is an 
over- and misused term and should be abandoned.  
 
Findings of this thesis are clinically important from several reasons. Firstly, neurotoxicity of 
thrombolysis with t-PA is increasingly appreciated and BBB protecting drugs are being 
sought. BBBP imaging may be useful in detecting AIS patients that are under risk of 
developing massive edema or hemorrhagic transformation. Furthermore, when testing BBB 
protective strategies, quantitative BBBP evaluations are needed to monitor therapeutical 
effects. Up to date, no neuroprotective or neurorestorative strategy is proven effective in AIS 
patients. However, experiences from past clinical trials revealed that there is much to 
improve in both preclinical studies and clinical trial designs.  With these improvements 
implemented, new drugs with potential long-term application may be offered to AIS patients. 
From this aspect, it is crucial to elucidate when the BBB is in ischemic stroke patients and for 
how long it remains so. MRI-based BBBP evaluation method used in this thesis may easily 
serve for this purpose. 
 
Stanniocalcin is yet a little-known molecule. Our findings emphasize the neuroprotective 
effect of STC1, through a cross-talk with inflammatory cytokine IL-6. However, STC1 does 
not appear to have a role in BBB integrity. 
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